WO1999057246A1 - Animal cell culture media comprising non-animal or plant-derived nutrients - Google Patents

Animal cell culture media comprising non-animal or plant-derived nutrients Download PDF

Info

Publication number
WO1999057246A1
WO1999057246A1 PCT/US1999/009574 US9909574W WO9957246A1 WO 1999057246 A1 WO1999057246 A1 WO 1999057246A1 US 9909574 W US9909574 W US 9909574W WO 9957246 A1 WO9957246 A1 WO 9957246A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
cell
culture medium
cell culture
derived
Prior art date
Application number
PCT/US1999/009574
Other languages
French (fr)
Other versions
WO1999057246A8 (en
WO1999057246A9 (en
Inventor
Paul J. Price
Steve Gorfien
Douglas Danner
Mark Plavsic
Original Assignee
Life Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Technologies, Inc. filed Critical Life Technologies, Inc.
Publication of WO1999057246A1 publication Critical patent/WO1999057246A1/en
Publication of WO1999057246A8 publication Critical patent/WO1999057246A8/en
Publication of WO1999057246A9 publication Critical patent/WO1999057246A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018Culture media for cell or tissue culture
    • C12N5/0043Medium free of human- or animal-derived components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/12Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/20Transition metals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/32Amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/36Lipids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/30Organic components
    • C12N2500/40Nucleotides, nucleosides, bases
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/74Undefined extracts from fungi, e.g. yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/70Undefined extracts
    • C12N2500/76Undefined extracts from plants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/90Serum-free medium, which may still contain naturally-sourced components
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10Growth factors
    • C12N2501/11Epidermal growth factor [EGF]

Definitions

  • the present invention generally relates to cell culture medium formulations. Specifically, the present invention provides cell culture medium formulations which comprise one or more non-animal derived peptides and more specifically one or more plant peptides for facilitating the in viti-o cultivation of animal cells.
  • the present invention also relates to media formulations which comprise one or more non-animal derived lipids and/or fatty acids, and more specifically one or more plant lipids and/or fatty acids for cultivation of animal cells in vitro.
  • the formulations of the invention may also comprise one or more of such non-animal or plant peptides and one or more of such non-animal or plant lipids and/or fatty acids.
  • non-animal or plant-derived peptides and non-animal or plant-derived lipids and/or fatty acids may be used as substitutes for one or more animal-derived culture media components.
  • the invention also provides methods for cultivating animal cells using these non-animal or plant nutrient-based culture media.
  • the media of the present invention arc particularly suited for virus production in animal cells.
  • Cell Culture Media Cell culture media provide the nutrients necessary to maintain and grow cells in a controlled artificial and in vitro environment.
  • the characteristics and compositions of the cell culture media vary depending on iho particular cellular requirements. Important parameters include osmolariry, pH, and nutrient formulations.
  • Media formulations have been used lo cultivate a number of cell types including animal, plant and bacterial cells.
  • Cells cultivated in culture media catabolize available nutrients and produce useful biological substances such as monoclonal antibodies, hormones, growth factors and the like. Such products have therapeutic applications and, with the advent of recombinunt DNA technology, cells can be engineered to produce large quantities of these products.
  • Cultured cells arc also routinely used for the isolation, identification and growth of viruses.
  • the ability to cultivate cells in vitro is not only important for the study of cell physiology, but is also necessary for the production of useful substances which may not otherwise be obtained by cost-effective means.
  • Typical components of cell culture media include amino acids, organic and inorganic salts, vitamins, trace metals, sugars, lipids and nucleic acids, the types and amounts of which may vary depending upon the particular requirements of a given cell or tissue type.
  • cell culture media formulations are supplemented with a range of additives, including undefined components such as fetal bovine scrum (FBS) (10-20% v/v) or extracts from animal embryos, organs or glands (0.5-10% v/v). While FBS is the most commonly applied supplement in animal cell culture media, other serum sources are also routinely used, including newborn calf, horse and human. These types of chemically undofi ⁇ cd supplements serve several useful functions in cell culture media (Lambert, K. J. ei al.. In: Animal Cell Biotechnology, Vol. 1, Spier, R. E. et al., Eds., Academic Press New York, pp. 85-122 (1985)).
  • FBS fetal bovine scrum
  • these supplements provide carriers or chelators for labile or water-insoluble nutrients; bind and neutralize toxic moieties; provide hormones and growth factors, protease inhibitors and essential, of t en unidentified or undefined low molecular weight nutrients; and protect cells from physical stress and 5- damage.
  • serum and/or animal extracts are commonly used as relatively low-cost supplements to provide an optimal culture medium for the cultivation of animal cells.
  • a major fear is the presence of prions causing spongiform ⁇ cnccphalopathy in humans or animals.
  • Cell surface chemistry which is a critical portion of the in vitro microcnvironment for many cell types, can be adversely modified via adsorption or incorporation of scrum or extract proteins.
  • undefined components such as serum or animal extracts also prevents the true definition and elucidation of the nutritional and hormonal requirements of the cultured cells, thus eUminating the ability to study, in a controlled way, the effect >0 of specific growth factors or nutrients on cell growth and differentiation in culture.
  • undefined supplements prevent the researcher from studying aberrant growth and differentiation and the disease-related changes in cultured cells.
  • scrum and animal extract supplementation of culture media can also complicate and increase the costs of purification of the desired substances from the culture media due to nonspecific co- 25 purification of scrum or extract proteins.
  • serum-free media which often are specifically formulated to support the culture of a single cell type, incorporate defined quantities of purified growth factors, lipoprotcins and other proteins usually provided by the scrum or extract supplement. Since the components (and concentrations thereof) in such culture media are precisely known, these media are generally referred to as “defined culture media” and often as “serum-free media” or "SFM.” ⁇ number of SFM formulations are commercially available, such as those designed to support the culture of cndothelial cells, keratinocytes, monocytes/macrophagcs, fibroblasts. neurons, lymphocytes, chondrocytes or hepalocytes which arc available from Life Technologies, inc. (Rockvillc, MD).
  • SFM generally provide several distinct advantages to the user. For example, the use of SFM facilitates the investigation of the effects of a specific growth factor or other medium component on cellular physiology, which may be masked when the cells are cultivated in serum- or cxtract- containing media. In addition, SFM typically contain much lower quantities of protein (SFM are often called "low protein media") than those containing serum or extracts, rendering purification of biological substances produced by cells cultured in SFM far simpler and more cost-effective.
  • SFM small cell culture
  • Such media (often called “basal media”), however, arc usually seriously deficient in the nutritional content required by most animal cells.
  • SFM incorporate additional components into the basal media to make the media more nutritionally complex, while maintaining the serum-free and low protein content of the media.
  • additional components include serum albumin from bovine (BSA) or human (HSA), animal- derived lipids such as human Excylc, sterols, etc., and certain growth factors or hormones derived from natural (animal) or recombinant sources.
  • supplements derived from the same species as the cells to be cultured may be used.
  • culture of human cells may be facilitated using HSA as a supplement, while media for the culture of bovine cells would instead use BSA.
  • his approach runs the risks of introducing contaminants and adventitious pathogens into the culture medium (such as HIV or Hepatitis B virus from HSA preparations, or Bovine Spongiform E ⁇ cephalopathy virus from BSA preparations), which cun obviously negatively impact the use of such media in the preparation of animal and human therapeutics.
  • the biotechnology industry anil government agencies are increasingly regulating, discouraging and even forbidding the use of cell culture media containing animal-derived products which may contain such pathogens.
  • wheat peptides are known to bo toxic or to induce toxic effects in vitro and in vivo, particularly in the cells and tissues of the gastrointestinal systems of some mammals, including humans (Strober, W., et al., Ann. Int. Med. 55:242-256 (1975); Auricchto, S., et al., Pcdiatr. lies. 22(6) 103-H77 (1987)).
  • extracts from certain plants, including wheat, barley, rye and oats have been shown to inhibit protein synthesis in cell-free systems derived from animal cells (Colcman, W.H., and Roberts, W.K..
  • a scrum-frcc, low-prntein culture medium suitable for cultivation of animal cells, which is completely devoid of animal or human proteins.
  • Such a medium formulation will facilitate the study of the effects of growth factors and other stimuli on cellular physiology, will allow easier and more cost-effective purification of biological substances produced by cultured animal cells in the biotechnology industry, and most importantly, will eliminate the risk of introduction of adventitious animal and human pathogens.
  • the present invention provides such an animal cell culture medium formulation
  • the present invention provides culture media formulations comprising non-animal or plant peptides that support the culture of animal cells, preferably as a primary protein source.
  • the invention provides a cell culture medium capable of supporting the cultivation of an animal cell in vitro, wherein the medium comprises at least one plant peptide which is not derived from wheat and which is most preferably derived from rice.
  • the media formulations of the invention comprise at least one non-animal or plant lipid and or fatty acid.
  • the media formulations of the invention comprise at least one non-animal or plant peptide and at least " one non-animal or plant lipid and/or fatty acid.
  • the invention also provides such media formulations which further comprise an enzymatic digest or extract of yeast cells.
  • flic invention also provides a cell culture medium, capable of supporting the cultivation of an animal cell in vitro, comprising an extract of yeast cells, wherein the medium does not further comprise a wheat-derived plant peptide.
  • the media of the present invention may be IX formulations, or may be concentrated as 10X- 100X, most preferably as 10X, 20X, 25X, 50X or 100X formulations.
  • the basal medium of the present Invention comprises a number of ingredients, including a ino acids, vitamins, organic and inorganic salts, sugars, each ingredient being present in an amount which supports the cultivation of an animal cell in vitro.
  • the medium of the invention may be used to culture a variety of animal cells, including insect cells (such as from the Spodoptera or Trichuplusa species), avion cells and mammalian cells (including primary cells, established cell lines, CHO cells, COS cells, VERO ceils, BHK cells and human cells).
  • insect cells such as from the Spodoptera or Trichuplusa species
  • avion cells including primary cells, established cell lines, CHO cells, COS cells, VERO ceils, BHK cells and human cells.
  • the present invention also provides methods of culturing animal and human cells using the culture medium formulations disclosed herein, comprising die steps of (a) contac t ing an animal cell with the cell culture medium or the present invention; and (b) cultivating the animal ceil
  • the present invention also relates to methods for replacing or substituting arumal-dcrived products with non-animal or plant-derived peptides, non-animal or plant lipids/fatty acids (or combinations thereoO, ⁇ nd/or enzymatic digests or extracts of yeast cells.
  • Such non-a ⁇ ii ⁇ al/pla ⁇ t- dcrivcd products may be substituted for any number of animal-derived products, including but not limited to blood-derived products (e.g., serum, albumin, antibodies, fibrinogen, factor VHI, etc.), tissue or organ extracts and/or hydrolysates (e.g., bovine pituitary extract (BPE), bovine brain extract, chick embryo extract and bovine embryo extract), and animal-derived lipids and fatty acids, peptones, Excyte, slerols (e.g., cholesterol) and lipoproteins (e.g., high-density and low-density lipoproteins (HDLs and LDI ⁇ s, respectively)).
  • blood-derived products e.g., serum, albumin, antibodies, fibrinogen, factor VHI, etc.
  • tissue or organ extracts and/or hydrolysates e.g., bovine pituitary extract (BPE), bovine brain extract, chic
  • compositions comprising the culture media of the present invention and an animal cell, including any of the animal cells described herein.
  • FIGURE 1 shows the effect of Plant Powder on the growth of Hybridomu P1F6.
  • Figure 2 shows the effect of Plant Powder on IgC production in Hybridoma P1F6.
  • Figure 3 shows the effect of Plant Powder on specific productivity of Hybridoma P1F6.
  • Cell culture refers to the maintenance of cells in an artificial, in vi t ro environment. It is to be understood, however, that the term “cell culture” is a generic term an d may be used to encompass the cultivation not only of individual cells, but also of tissues, organs, organ systems or whole organisms, for which the terms "tissue culture,” “organ culture,” “organ system culture” or “organotypic culture” may occasionally be used interchangeably with the term “cell culture.”
  • culture refers to the maintenance of cells in vitro under conditions favoring growth, differentiation or continued viability, in an active or quiescent state, of the colls. In this sense, “cultivation” may be used interchangeably with “cell culture” or any of its synonyms described above. 5
  • culture vessel refers to a glass, plastic, or metal container that can provide an aseptic environment for culturing cells.
  • contacting refers to the placing ol cells to be cultivated in vitro into a culture vessel with the medium in which the cells are to be cultivated.
  • the term “contacting” encompasses mixing cells with medium, pipetting medium onto cells in a culture vessel, and submerging cells in culture medium.
  • combining refers to the mixing or admixing of ingredients in a cell culture medium formulation.
  • cytokine refers to a compound that induces a physiological response in a cell, uch as growth, differentiation, senescence, apoplosis, cytotoxicity or antibody secretion. Included 5 in this definition of "cytokine” arc growth factors, interleuki ⁇ s, colony-stimulating factors, interferons and lymphokines.
  • enzyme digest refers to a composition comprising a specialized type of extract, namely one prepared by treating the substance to he extracted (e.g., plant components or yeast cells) with at least one enzyme capable of breaking down the components of die substance into simpler -. J forms (e.g., into a preparation comprising mono- or disaccharid s and/or mono-, di- or tripeptides).
  • hydrolysate may be us e d interchangeably with the term "enzymatic digest.”
  • extract refers to a composition comprising a concentrated preparation of the components of a substance, typically formed by treatment of the substance cither mechanically (e.g., by pressure treatment) or chemically (e.g., by distillation, precipitation, enzymatic action or high salt treatment).
  • lipid refers generally to water-insoluble organic molecules that can he extracted from cells and tissues by nonpolar solvents. Lipids are generally classified as complex lipids (which contain fatty acids) or simple lipids (which do not contain fatty acids).
  • the complex lipids include acylglycerols, phosphoglyceridcs, sphingolipids and waxes.
  • the simple lipids include terpcncs, steroids and prostaglandins. Tcrpc ⁇ es include compounds such as geraniol, limonene, menthol, pinene, camphor and carvone.
  • Steroids include the subgroup "sterols,” which are steroid alcohols containing a hydroxyl group and a branched aliphatic chain of eight or more carbon atoms. See generally, Lchningcr, Albert L., Biochemistry, Worth Publishers, Inc. New York, pp. 279-306 (1975), which is herein incorporated by reference.
  • the term "ingredient” refers to any compound, whether of chemical or biological origin, that can be used in cell culture media to maintain or promote the growth or proliferation of cells.
  • component “nutrient” and “ingredient” can be used interchangeably and are all meant to refer to such compounds.
  • Typical ingredients that are ⁇ sed in cell culture media include amino acids, salts, metals, sugars, lipids, nucleic acids, hormones, vitamins, fatty acids, proteins and the like. Other ingredients that promote or maintain cultivation of cells ex vivo can be selected by those of skill in the art in accordance with the particular need.
  • non-animal derived refers to the origin of the compound, molecule, peptide, lipid, fatty acid, etc. of interest.
  • non-animal sources may include chemical synthesis or synthetic preparations or isolation, preparation or purification of the compound, molecule, peptide, lipid, fatty acid, etc. of interest from bacteria, yeast fungi, and plants.
  • a cell culture medium is composed of a number of ingredients and these ingredients vary from one culture medium to another.
  • a "IX formulation” refers to any aqueous solution that contains some or all ingredients found in a cell culture medium at working concentrations.
  • the "IX formulation” can refer to, for example, the cell culture medium or to any subgroup of ingredients for that medium.
  • the concentration of an ingredient in a IX solution is about the same as the concen ⁇ tration of that ingredient found in a cell culture formulation used for maintaining or cultivating cells in vitro.
  • a cell culture medium used for the in vitro cultivation of cells is a IX formulation by definition. When a number of ingredients are present, each ingredient in a IX formulation has a concentration about equal to the concentration of those ingredients in a cell culture medium.
  • RPMl-1640 culture medium contains, among other ingredients, 0.2 g L L-arginine, 0.05 g/L L-asparagine, and 0.02 g L L-aspartic acid.
  • a "IX formulation" of these amino acids contains about the same concentrations of these ingredients in solution.
  • each ingredient in solution has the same or about the same concentration as that found in the cell culture medium being described.
  • concentrations of ingredients in a IX formulation of cell culture medium are well known to those of ordinary skill in the art. See Allen R. Liss, Methods For Preparation of Media, Supplements and Substrate For Serum-Free Animal Cell Culture, N.Y. (1984), which is incorporated herein by reference in its entirety.
  • the osmolarity and or pH may differ in a IX formulation compared to the culture medium, particularly when fewer ingredients are contained in the IX formulation.
  • a "10X formulation” refers to a solution wherein each ingredient in that solution is about 10 times more concentrated than the same ingredient in the cell culture medium.
  • a 10 formulation of RPMT-1 40 culture medium may contain, among other ingredients, 2.0 g L L- argininc, 0.5 g/L L-asparagine, and 0.2 g/L L-aspartic acid (compare IX formulation, above).
  • a "10X formulation” may contain a number of additional ingredients at a concentration about 10 times that found in the IX culture medium.
  • "20X formulation,” “25X formulation,” “50X formulation” and “100X formulation” designate solutions that contain ingredients at about 20-, 25-. 50- or 100- fold concentrations, respectively, as compared to a IX cell culture medium. Again, the osmolarity and pH of the media formulation and concentrated solution may vary.
  • the cell culture media of the present invention are aqueous-based and comprise a number of ingredients in a solution of dcionizcd, distilled water to form a "basal media.” Any basal medium can be used in accordance with the present invention.
  • the basal media of the present invention may - include the following ingredients: ami ⁇ o acids, vitamins, organic and/or inorganic salts, trace elements, buffering salts and sugars.
  • the basal media of the invention comprise one or more amino acids, one or more vitamins, one or more inorganic salts, adcnine sulfate, ATP, one or more trace elements, dcoxyribose, ethanolami ⁇ e, D-gluco ⁇ c, glutathione, N-[2-hydroxycthyl]- piperazine-N'-[2-ethancsulfonic acid] (HEPES) or one or more other zwitterion buffers, hypoxanthinc, linoleic acid, lipoic acid, insulin, phenol red, phosphoethanolaminc, putrescine. sodium pyruvalc, thymidi ⁇ e, uracil and xanthine. Each of these ingredients may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
  • Amino acid ingredients which may bo included in the media of the present invention include
  • L-alanine L-argini ⁇ , L-asparagine, L-aspartic acid, L-cysti ⁇ e, L-cystcinc, L-glutamic acid, L-gluiamine, glycine, L-histidinc, L-isolcucine, L-Ieuci ⁇ e, L-lysinc, L-mcthionine, L-phenylalanine,
  • L-proline I ⁇ -serinc, L-thrconine, L-lryptophan, L-tyrosine and L-valinc.
  • amino acids may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
  • Vitamin ingredients which may be included in the media of the present invention include ascorbic acid magnesium salt, biotin, choli ⁇ e chloride, D-Ca ⁇ -pantothenate, folic acid, Mnositol, menadione, niacinamidc, nicotinic acid, paraaminobenzoic acid (PABA), pyridoxal, pyridoxinc, rihoflavin, t iaminc-HCl, vitamin A acetate, vitamin B
  • vitamins may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
  • Inorganic salt ingredients which may be used in the media of the present invention include CaCl 2 , KC1, MgCl 2 , MgSO 4 , NaCl, NaHCOj, Na z HP0 4 , a ⁇ PO ⁇ -IIzO and ferric citrate cheiate or ferrous sulfate chelatc. These inorganic salts may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
  • Trace elements which may be used in the media of the present invention include ions of barium, bromium, cobalt iodine, manganese, chromium, copper, nickel, selenium, vanadium, titanium, germanium, molybdenum, silicon, iron, fluorine, silver, rubidium, tin, zirconium, cadmium, zinc and aluminum. These ions may be provided, for example, in trace element salts such
  • Cyt ⁇ ki ⁇ es which may be used in the media of the present invention include growth factors such as epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hcpatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-I), insulin- like growth factor 2 (IGF-2), kcratinocyte growth factor (KGF), nerve growth factor (NGF), platelet- derived growth factor (PDGF), transforming growth factor beta (TGF- ⁇ ), vascular endotheiial cell growth factor (VKGF), transferrin, various i ⁇ terleukins (such as IL-1 through IL-18), various colony- stimulating factors (such as granulocyte/macrophage colony-stimulating factor (GM-CSF)), various intcrferons (such as IFN-v) and other cytokines having effects upon hcmatopoletic stem cells such as stem cell factor (SCF) and crythropoictin (
  • cytokines may be obtained commercially, for example from Life Technologies, Tnc. (Rockville. Maryland) or R&D Systems (Minneapolis, Minnesota), and may bo citiier natural or rucoinbinant Most preferably, for culture of a wide variety of rruurimalian cells, the basal media will contain EGF at a concentration of about 0.1-100 nanograms/m i 11 i 1 i ter, preferably about 1-10 nanograms/milliliter, and most preferably about 5-10 nanograms per milliliter. Other cytokines, if used, may be added at concentrations that are determined empirically or as guided by the established cytokine art.
  • Additional ingredients that may be included in the present media are insulin (especially as insulin»Zn ++ and transferrin. These additional ingredients, available commercially (for example, from Sigma, St. Louis, Missouri), may be formulated into the present media at the concentration ranges and preferred concentrations shown in Table 1.
  • An iron salt or chclatc e.g., ferric citrate chclatc or ferrous sulfate
  • rccombinant insulin or zinc based salts e.g., ZnCl etc.
  • ZnCl zinc based salts
  • basal medium When admixed together in solution, form a "basal medium.”
  • Other basal media can be cquivalently used in accordance wi ⁇ i the present invention.
  • at least one peptide, extract, enzymatic digest or hydrolysate of a non-animal or a plant and particularly of a plant protein, and/or at least one non-animal -derived or plant-derived lipid and/or fatty acid is added to the basal medium to formulate the complete culture media of the present invention.
  • Plants suitable as sources of proteins, peptides, lipids and/or fatty acids in formulating the culture media of the present invention include, but are not limited to, rice, soy, potato, corn and aloe vera. Particularly preferred as a source of plant protein i.s rice.
  • the use of wheat as a source of plant-derived proteins is specifically excluded from the present invention, as extracts and peptide preparations from wheat have been shown to contain inhibitors of protein synthesis in animal cell systems (Coleman, W.H., and Roberts, W.K., Biochim. Biophys.
  • Non-animal or plant peptides for use in formulating the culture media of the present invention may be prepared by digesting non-animal or plant extracts with enzymes such as trypsin or chymotrypsin by methods that are routine in the art.
  • enzymes such as trypsin or chymotrypsin
  • peptides in the form of enzymatic digests or hydrolysates may be obtained commercially, for example from Quest International (Norwich, New York).
  • Non-animal or plant peptides are added to the basal medium at a concentration of about 10-1000 mg/litcr, preferably about 50-500 mg/litcr, and most preferably about 100-200 mg liter.
  • Non-animal or plant lipids fatty acids suitable for use in the present culture media may be obtained from any of the above-described plant sources and others that will be familiar to one of ordinary skill, and from bacteria, yeast and fungi, using methods of lipid/fatty acid isolation (for example, extraction, chromatography, particularly HPLC and the like) that arc well-known in the art
  • plant as well as non-animal lipids/fatty acids and complexes of lipids and/or fatty acids may be obtained commercially, for example from Matreya. Inc. (Pleasant Gap, Pennsylvania) or Sigma (Saint Louis, Missouri).
  • Fatty acids (or combinations thereof) for use in the invention include saturated and unsaturatcd fatty acids.
  • Unsaturatcd fatty acids include monoenic acids, dienoic acids, and higher fatty acids (e.g., tri, tetra, penta and hexaenoic acids, etc.). See generally, Ixhningcr, supra.
  • Particularly preferred lipids/fatty acids for use in the present culture media include, but are not limited to, palmitate, slearate. oleate. linoleate.
  • plant-derived sterols known as phytosterols
  • fungi- and yeast-derived sterols known as mycosterols
  • mycosterols may be used as the lipid ingredient according to the present invention.
  • non-animal derived sterols include, but are not limited to, brassicastcrol, campesterol, desmosterol, ergosterol, fucosterol, lanosterol, stigmastanol ( ⁇ -sitostcrol), sitosterol, stigmasterol and stigmasterol acetate, all of which arc commercially available, for example from Matreya, Inc. (Pleasant Gap, Pennsylvania) or Sigma (Saint Louis, Missouri).
  • These lipids/fatty acids may be added individually or as mixtures comprising two or more of the above-described lipids/fatty acids, preferably in specific proportions as described in more detail below.
  • non-animal or plant lipids/fatty acids are added to a basal medium a t concentrations of about 0.00001 to about 10,000 ⁇ g/ml, more preferably about 0.0001 to about j 1000 ⁇ g/ml, and most preferably ahout 0.001 to about 100 ⁇ g/ml.
  • the basal medium including non-animal or plant-derived peptides and or non- animal or plant-derived lipids/fatty acids formulate complete culture media according to the present invention.
  • These complete media are suitable for use in the culture of a variety of animal cells, as described in more detail below. It may be preferable, however, to further enrich the nutritional l ⁇ content of the complete media to support faster growth and enhanced production of biologicals by the cultured cells, and to provide a more suitable environment for the culture of fastidious animal cells. To accomplish such enrichment, one or more additional nutrients derived from non-animal sources may be added to the above-described basal or complete media.
  • the additional nutrients added to the basal medium ⁇ or complete medium may comprise extracts of yeast cells (hereinafter “yeast extract” or “YE”), and most preferably ure ultrafiltered YE (hereinafter “yeast extract ultrafiltrate” or “YEU”).
  • yeast extract extracts of yeast cells
  • YEU ure ultrafiltered YE
  • Such extracts may be prepared by methods generally known to those skilled in the art of bacteriological or animal cell culture medium formulation, or may be obtained commercially, for example from Sigma (Saint Louis, Missouri), Difco (Norwood, Massachusetts) or Quest International (Norwich, New :0 York).
  • YE or YEU are added to the basal or complete media described above at concentrations of about 10-8000 mg/liter, preferably about 10-100 mg litcr, and most preferably about 50-100 mg/liter.
  • YE or YEU may be added to the basal media at these concentrations, in the absence of whcat-dcrivcd plant peptides, enzymatic digests of animal proteins and peptones, to formulate a suitable animal cell culture medium according to the present invention.
  • the medium ingredients can be dissolved in a liquid carrier or maintained in dry form.
  • the pH of the medium should be adjusted to about 7.0-7.5, preferably about 7.1-7.4, and most preferably about 7.1-7.3.
  • the osmolarity of the medium should also be adjusted to about 275-350 mOsm, preferably about 285-325 mOsm, and most preferably about 300-325 uiOsui.
  • the 0 type of liquid carrier and the method used to dissolve the ingredients into solution vary and can be determined by one of ordinary skill in the art with no more than routine experimentation. Typically, the medium ingredients can be added in any order.
  • the solutions comprising ingredients arc more concentrated than the concentration of the same ingredients in a IX media formulation.
  • the ingredients can be 10- fold more concentrated (10X formulation), 20-fold more concentrated (20X formulation), 25-fold more concentrated (25X formulation), 50-fold more concentrated (50X concentration), or 100-fold more concentrated (100X formulation). More highly concentrated formulations can be made, provided that the ingredient! remain soluble and stable. Sec U.S. Patent No. 5,474,931, which is directed to methods of solubilizing culture media components at high concentrations. Tf the media ingredients arc prepared as separate concentrated solutions, an appropriate
  • the diluent used Is water, but other solutions including aqueous buffers, aqueous saline solution, or other aqueous solutions may be used according to the invention.
  • the culture media of the present invention are typically sterilized to prevent unwanted contamination. Sterilization may be accomplished, for example, by filtration through a low protein- binding membrane filter of about 0.1-1.0 ⁇ m pore size (available commercially, for example, from Milliporc, Bedford, Massachusetts) after admixing the concentrated ingredients to produce a sterile culture medium. Alternatively, concentrated subgroups of ingredients may be filter-stcrilizcd and stored as sterile solutions. These sterile concentrates can then be mixed under aseptic conditions with a sterile diluent to produce a concentrated IX sterile medium formulation. Autoclaving or other elevated temperature-based methods of sterilization are not favored, since many of the components of the present culture media arc heat labile and will be irreversibly degraded by temperatures such as those achieved during most heat sterilization methods.
  • the optimal concentration ranges for the basal medium ingredients are listed in Table 1. These ingredients can be combined to form the basal animal cell culture medium which is then supplemented with cytokines, non-animal or plant peptides and optionally (but preferably) with YE, YEU and or one or more non-animal or plant lipids/fatty acids (or combinations thereof), to formulate the complete media of the present invention.
  • cytokines non-animal or plant peptides
  • YE, YEU optionally (but preferably) with YE, YEU and or one or more non-animal or plant lipids/fatty acids (or combinations thereof)
  • concentration of a given ingredient can be increased or decreased beyond the range disclosed and the effect of the increased or decreased concentration can be determined using routine experimentation.
  • the concentrations of the ingredients of the medium of the present invention are the concentrations listed in the far right column of Table 1, supplemented with cytokines, non-animal or plant peptides and YE, YEU and/or one or more non- animal or plant lipids/fatty acids as described above.
  • each of the components of the culture medium may react with one or more other components in the solution.
  • the present invention encompasses the formulations disclosed in Table 1, supplemented as described above, as well as any reaction mixture which forms after these ingredients arc combinod.
  • the optimization of the present media formulations was carried out using approaches 0 described by Ham (Ham, R.G., Metlwd for Preparation of Media, Supplements and Substrata for Serum-Free Animal Culture, Alan R. Liss, Inc., New York, pp. 3-21 (1984)) and Waymouth (Waymouth, C, Methods for Preparation of Media, Supplements and Substrata fur Serum-Free Animal Culture, Alan R. Liss, Inc., New York, pp. 23-68 (1984)).
  • the optimal final concentrations for medium ingredients are typically identified either by empirical studies, in single component (5 titration tudies, or by interpretation of historical and current scientific literature. In single component titration studies, using animal cells, the concentration of a single medium component i.s varied while all other constituents and variables arc kept constant and the effect of the single component on viability, growth or continued health of the animal cells is measured.
  • the present invention also relates to methods for replacing or substituting animal-derived 20 products with non-animal or plant peptides, non-animal or plant lipids and/or fatty acids, and/or enzymatic digests or extracts of yeast cells (or combinations thereof).
  • Such non-animal-, plant- and or yeast-derived nutrients may be substituted for any number of animal-derived culture medium components or sub tituents, including but not limited to blood-derived products, tissue organ/gland extracts, animal-derived fatty acids and lipids, sterols, and lipoproteins.
  • blood-derived 25 products and tissue/organ extracts are substituted in the culture media of the invention using one or more of the above-described non-animal or plant-derived peptides, while animal-derived fatty acids/lipids, sterols and lipoproteins arc preferably substituted with one or more of the above- described non-animal or plant-derived lipids fatty acids.
  • Typical blood-derived products that may be replaced in accordance with this aspect of the invention include but are not limited to serum (e.g., 2D fetal bovine serum and calf serum, human scrum, etc.), plasma, albumin (e.g., bovine scrum albumin or human serutn albumin), antibodies, fibrinogen, factor VIU, etc.
  • Typical tissuc/organ gland extracts that may be replaced in accordance with this aspect of the invention include but are not limited to bovine pituitary extract (BPE), bovine brain extract, chicken embryo extract and bovine embryo extract.
  • BPE bovine pituitary extract
  • bovine brain extract bovine brain extract
  • chicken embryo extract bovine embryo extract
  • bovine embryo extract any animal-derived fatty acid or lipid, including saturated and unsaturated fatly acids lipids that are well-known in the art, may be replaced with one or more of the above-described non-animal or plant-derived lipids/fatty acids.
  • animal- derived sterols e.g., cholesterol
  • lipoproteins e.g., high- and low-density lipoproteins (HDLs and LDLs, respectively)
  • HDLs and LDLs high- and low-density lipoproteins
  • animal-derived medium components which may be replaced by one or more non-animal or plant-derived nutrients in accordance with the invention can be easily determined by one of ordinary skill in the art by substituting one or more non-animal or plant lipids/fatty acids, non-animal or plant peptides and/or extracts/digests of yeast (or combinations thereof) and testing the effect of such substitution on cell growth by methods that will be familiar to the ordinarily skilled artisan (such as those methods described in the examples below).
  • the present invention further relates to a kit for replacing one or more ariimal-derived ingredients in a cell culture medium, wherein the kit comprises one or more non-ariimal or plant derived peptides and/or one or more non-animal or plant-derived lipids or fatty acids or combinations thereof.
  • Cells which can be cultivated in the medium of the present invention are those of animal origin, including but not limited to cells obtained from mammals, birds (avian), insects or fish.
  • Mtujimalian cells particularly suitable for cultivation in the present media include those of human origin, which may be primary cells derived from a tissue sample, diploid cell strains, transformed cells or established cell lines (e.g., HeLa), each of which may optionally be diseased or genetically altered.
  • Other miunmalian cells uch as hybridomas, CIIO cells, COS cells, VERO cells, IleLa cells, 293 cells, PER-C6 cells, K562 cells, MOLT-4 cells, Ml cells, NS-1 cells.
  • COS-7 ceils are also suitable for cultivation in the present media.
  • stem cells and cells used in in vitro virus production may be cultivated in the media of the present invention.
  • Insect cells particularly suitable for cultivation in the present media include those derived from Spodoptera species (e.g., Sf9 or S/21, derived from Spodopteru frugiperdd) or richoplusa species (e.g., HIGH FIVETM or MG1, derived from Trichoplusa ni).
  • Tissues, organs, organ systems and organisms derived from animals or constructed in vitro or in vivo using methods routine in the art may similarly be cultivated in the culture media of the present invention.
  • Animal cells for cultiiring by the present invention may be obtained commercially, for example from ATCC (Rockville, Maryland), Cell Systems, Inc. (Kirkland, Washington) or Invitrogcn Corporation (San Diego, California). Alternatively, cells may be isolated directly from samples of animal tissue obtained via biopsy, autopsy, donation or other surgical or medical procedure.
  • Tissue should be handled using standard sterile technique and a laminar flow safety cabinet. In the use and p ocessing of all human tissue, the recommendations of the U.S. Department of Health and Human Services Centers for Disease Control and Prevention should be followed (Bios fety in Microbiological tmd Binmedical Laboratories, Richmond, J.Y. et al, Eds., U.S. Government Printing Office, Washington, D.C. 3rd Edition (1993)). The tissue should be cut into small pieces 1 (e.g., 0.5 x 0.5 cm) using sterile urgical instruments.
  • the small pieces should be washed twice with sterile saline solution upplemented with antibiotics as above, and then may be optionally treated with an enzymatic solution (e.g., collagenase or trypsin solutions, each available commercially, for example, from Lire Technologies, Inc., Rockville, Maryland) to promote dissociation of cells from the tissue matrix.
  • an enzymatic solution e.g., collagenase or trypsin solutions, each available commercially, for example, from Lire Technologies, Inc., Rockville, Maryland
  • the mixture of dissociated cells and matrix molecules are washed twice with a suitable physiological saline or tissue culture medium (e.g., Dulbccco' Phosphate Buffered Saline without calcium and magnesium). Between washes, the cells arc ccntrifugcd (e.g., at 200 x g) and then re- suspcnded in serum-free tissue culture medium. Aliquots are counted using an electronic cell counter (such as a Coulter Counter). Alternatively, the cells can be counted manually using a hcmocytometer.
  • tissue culture medium e.g., Dulbccco' Phosphate Buffered Saline without calcium and magnesium.
  • the isolated cells can be plated according to the experimental conditions determined by the investigator.
  • the examples below demonstrate at least one functional set of culture conditions useful for cultivation of certain mammalian cells. It is to be understood, however, that the optimal plating Z and culture conditions for a given animal cell type can be determined by one of ordinary skill in the art using only routine experimentation. For routine culture conditions, using the present invention, cells can be plated onto the surface of culture vessels without attachment factors.
  • the vessels can be pre-coatcd with natural, recombinant or synthetic attachment factors or peptide fragments (e.g., collagen or ribronectin, or natural or ynthetic fragments thereof)- Isolated ceils can 0 also be seeded into or onto a natural or syntiietie three-dimensional support matrix such as a preformed collagen gel or a synthetic biopolymeric material, or onto feeder layers of cells.
  • attachment factors or a support matrix with the medium of the present invention will enhance cultivation of many attachment-dependent cells In the absence of serum supplementation.
  • the cell seeding densities for each experimental condition can be optimized for the specific culture conditions being used. For routine culture in plastic culture vessels, an initial seeding density of O. l-l.O x 10 % cells per cm z or about 1.5X the plating concentration routinely used for the ame cells in serum supplemented media i.s preferable.
  • Mammalian cells arc typically cultivated in a cell incubator al about 37"C, while the optimal temperatures for cultivation of avian, nematodc and insect cells are typically somewhat lower and arc 2 0 well-known to those of ordinary skill in the an.
  • the incubator atmosphere should be humidified for cultivation of animal cells, and should contain about 3-10% carbon dioxide in air.
  • Culture medium pH should be in the range of about 7.1-7.6, preferably about 7.1-7.4, and most preferably about 7-1- 7.3.
  • Cells in closed or batch culture should undergo complete medium exchange (i.e., replacing 2 5 spent media with fresh media) about every 2-3 days, with more or less frequently as required by the specific cell type.
  • Cells in pcrfusion culture e.g., in bioreactors or fe ⁇ nentcrs
  • the cell culture media of the present invention may also be used to produce cell culture composiiion.s comprising the present media and one or more animal cells.
  • Animal cells preferably used in such compositions include, but arc not limited to, cells obtained from mammals, birds (avian), insects or fish.
  • Mammalian cells particularly suitable for use in such compositions include those of human origin, which may be primary cells derived from a tissue sample, diploid cell trains, transformed cells or established cell lines (e.g., HeLa), each of which may optionally be diseased or genetically altered.
  • mammalian cells such as hybridomas, CHO cells, COS cells, VERO cells, HeLa cells, 293 cells, PER-C6 cells, K562 cells, MOLT-4 cells, Ml cells, NS-1 cells, COS-7 cells, MDBK cells, MDCK cells.
  • MRC-5 cells, WI-38 cells, SP2/0 cells, BHK cells (including BHK-21 cells) and derivatives thereof, are also suitable for use in forming the cell culture compositions of the present invention.
  • Insect cells particularly suitable for use in forming such compositions include those derived from Sp ⁇ d ⁇ ptera species (e.g., SJ or SJ2I, derived from Spad ⁇ ptcra frugiperda) or Trichoplusa species (e.g., HIGH FIVETM or MG1, derived from Trichoplusa nt). Tissues, organs, organ systems and organisms derived from animals or constructed in vitro or in vivn using methods routine in the art may similarly be used t ⁇ form the cell culture compositions of the present invention. These cell culture compositions may be used in a variety of medical (including diagnostic and therapeutic), industrial, forensic and research applications requiring ready-to-use cultures of " animal cells in scrum-free media.
  • Sp ⁇ d ⁇ ptera species e.g., SJ or SJ2I, derived from Spad ⁇ ptcra frugiperda
  • Trichoplusa species e.g., HIGH FIVETM or MG1, derived from Trichoplusa nt.
  • VERO cultures ATCC were plated in 25 cm 2 ceil culture flasks in duplicate in each medium at about 2.5 x l ⁇ ceils per flask in 5 ml of medium. No attachment factors or coating of the plastic surface are required for the culture of VERO cells. At 3 to 4 days the cells were removed using standard cell culture techniques. The surface of the culture was first washed with Dulbecco's Phosphate Buffered Saline (DPBS) and then 1.0 ml Trypsin-EDTA (Life Technologies, Inc., Rockville, Maryland) was added.
  • DPBS Dulbecco's Phosphate Buffered Saline
  • the digest was allowed to sit on the cell surface for 3 to 5 minutes or until the cells rounded up and began to detach from the surface of the flask.
  • the cells were completely detached by vigorous agitation against the palm of the hand and then 1.5 ml of soybean trypsin inhibitor was added to quickly neutralize enzymatic activity.
  • the cells were counted under the microscope using trypan blue straining solution and new cultures plated at 2.5 x 10 5 cells per 25 cm 2 flask. Incubation was at 37°C in 5% CO 2 in air.
  • the cultures were passaged for a total of 4 subcultures and the mean cells per subculture determined from the counts of the final 3 subcultures (P2 + P3 + P4 + 3).
  • ddH 2 O deionizcd water
  • trace elements from lOOOx stock
  • L-alaninc (0.22 g)
  • L-argini ⁇ e-HCl 9.75 g
  • L-asparagine-IICl (1.02 g)
  • L-aspartic acid 0.332 g
  • L-cysteine-HCI-H 2 O 0.10 g
  • L-cystine-HCl (2.87 g)
  • glycine (0.188 g)
  • L-glutamic acid 0.268 g
  • L-histidine-HCl-H 2 O (1.707 g), (4284 g)
  • L-leuci ⁇ e (4.511 g)
  • L-lysine-HCl 5.640 g)
  • L-methionine 1.266
  • the solution was gently mixed by magnetic stirring for about 15 minutes.
  • the pH of the solution was then adjusted to about 5.50 by adding a sufficient volume (about 20-25 iid) of 5N NaOH.
  • NaH*PO rt (7.494 g), NaiHPO 4 (1.175 g) and ascorbic acid Mg salt (1.25 g) were added and the solution was again gently mixed for about 15 minutes.
  • the pH was then adjusted to about 6.5 withS aOH.
  • ATP (0.025 g), uracil (0.0075 g), PABA (0.0012 g), D-Ca ⁇ -pantothcnatc (0.05 g), riboflavin (0.005 g), NaCi ( 142.50 g), CaCl 2 (3.00 g). MgCl 2 (3.125 g) and EGF (0.00025 g) were then added.
  • the solution was again gently mixed for about 15 minules, during which lime a 20 nil volume of absolute ethanol was obtained, to which were added vitamin A acetate (0.0035 g), vitamin D2 (0.0025 g), menadio ⁇ e (0.00025 g), lipoic acid (0.0019 g) and linoleic acid (0.00088 g). After allowing the compounds to dissolve in the ethanol, the ethanol solution was added to the 20 liter medium solution from above, and the medium solution was gently mixed for about 5 minutes.
  • Biotin (0.0019 g), folic acid (0.05 g), hypoxanthinc-Na (0.0415 g), xanthine-Na (0.0075 g) and insulin-Zn ++ (0.125 g) were added to a 20 ml volume of ddH 2 O. After allowing the compounds to dissolve in the water, this water solution was added to the 20 liter medium solution from above, and the medium solution was gently mixed for about 5 minutes. The pH r the solution was then adjusted with 5N HC1 or 5N NaOH to about 7.15 ⁇ 0.50.
  • VERO cells were cultured in the various medium formulations, and cell counts determined, as described above, and were compared to those obtained in basal medium that was unsupplemented (negative control) or supplemented with 500 mg/litcr human scrum albumin (HSA; positive control). Results shown in Table 2 demonstrate mean cell count per 25 cm 7 flask over 3 subcultures and relative growth efficiency (RGE) for each or the medium formulations. RGE was calculated by dividing the mean cell count for a given medium formulation by that for the HSA control.
  • yeast extract as a supplement in the present media preparations of YE or an ultrafiltrate of YE ("YEU") were supplemented into basal media in the presence or absence of 100 mg liler of rice hydrolysate. These media were then used to examine VERO cell growth as described above, Cell counts were compared to those obtained in EMEM supplemented with 5% FBS (positive control). Results shown in Table 5 demonstrate mean cell count and relative growth efficiency (RGE) for each of the medium formulations. RGE was calculated as described in Example 2.
  • - rice indicates medium not supplemented with 100 mg/L rice hydrolysate.
  • + rice indicates medium supplemented with 100 mg/L rice hydrolysate.
  • Example 2 To examine the effect of growth factor concentration on the performance of the culture media, recombinant human EGF was added to the basal media of Example 1 at various concentrations. These media were then used to examine VERO cell growth as described above. Cell counts were compared to those obtained in basal medium that was unsupplemented (negative control) or to EMEM supplemented with 5% FBS (positive control). Results shown in Table 6 demonstrate mean cell count and relative growth efficiency (RGE) for each of the EGF concentrations. RGE was calculated as described in Example 2.
  • an optimal culture medium formulation for supporting the cultivation of animal cells is the basal medium formulation shown in Table 1, supplemented with EGF at 5-10 mg/liter, yeast extract (preferably yeast extract ultrafiltrate) at 50-100 mg/liter, and at least one plant peptide (preferably rice peptides or hydrolysate) at 100-200 mg/liter.
  • Table 9 shows the use of the medium to grow BHK-21 cells in suspension on a shaker platform.
  • 0.2% PLURON1C F68 was added to both the test medium and the EMEM FBS 5% control to reduce shear damage. Counts were made at 72, 96 and 120 hours. As can be scon in Table 9 the test medium performed as well as or better than the control. By 120 hrs the viability began dropping much more rapidly in the control scrum-supplemented medium as compared to this preferred embodiment of the present invention.
  • culture media made as described in Example 1 were used to culture VERO cells.
  • Cells were plated in T-25 flasks into culture media that were not supplemented with plant-derived lipids or fatty acids (control) or that were supplemented with 5 ⁇ g ml, 0.5 ⁇ g/ml or 0.05 ⁇ g/ml of one of the following plant lipid or fatty acid mixes obtained from Matreya Inc. (Pleasant Gap, Pennsylvania), having constituents present in the indicated percentages:
  • RM-1 palmitate (6.0%), stcarate (3.0%), oleate (35.0%), linoleate (50.0%), linolenate (3.0%), arachidate (3.0%)
  • RM-2 palmitate (7.0%), stcarate (5.0%), oleate (18.0%), linoleate (36.0%), linolenate (34.0%)
  • RM-3 myrlstate (11.0%), palmitate (4.0%), siearate (3.0%), oleate (45.0%), linoleate (15.0%), linolenate (3.0%), arachidate (3.0%), behenatc (3.0%), erucate (20.0%), lignocer te (3.0%)
  • RM-5 caprylate (7.0%), caprate (5.0%), laurate (48.0%), myristatc (15.0%), palmitate (7.0%), stcarate (3.0%), oleate (12.0%), linoleate (3.0%)
  • RM-6 myristate (2.0%), palmitate (30.0%), palmitolcatc (3.0%), stcarate (14.0%), oleate ( 1 .0%), linoleate (7.0%), linolenate (3.0%)
  • the flasks were placed in a 37°C incubator in a humidified atmosphere of 8% C ⁇ 2 in air and subcultured every 2 to 3 days for 3 passages.
  • replicate T-75 flasks were set up and samples were taken on days 3, 4 and 5 post planting for determination of total cell density, viable cell density and IgG expression.
  • the samples that were used for IgG determination were oentrifuged and the supcrnatants stored al -20°C until assayed. IgG levels were estimated by ELISA using one sample from each of the replicate samples.
  • the Plant Powder had a positive effect on viable cell density in a dose- depcndcnt manner. Additionally, IgG expression was also improved by addition of the Plant Powder in a dose-dependent manner as seen in Figure 2. Furthermore, as seen in Figure 3, the specific productivity ( ⁇ g IgG/10 6 total cells) was slightly increased in the Plant Powder cultures, with the effect most pronounced on day 5 post planting.

Abstract

The present invention provides serum-free cell culture media formulations which are capable of supporting the in vitro cultivation of animal cells. The media comprise at least one nutrient of non-animal derivation, such as at least one plant peptide and/or at least one non-animal or plant lipid and/or fatty acid. The media may further optionally comprise an enzymatic digest or extract of yeast cells. The present invention also provides methods of cultivating animal cells in vitro using these cell culture media formulations. In addition, the media of the present invention can be used for growth of animal cells for virus production.

Description

Animal Cell Culture Media Comprising Non-Animal or Plant-Derived Nutrients
BACKGROUND OF THE INVENTION
ield of the Invention
The present invention generally relates to cell culture medium formulations. Specifically, the present invention provides cell culture medium formulations which comprise one or more non-animal derived peptides and more specifically one or more plant peptides for facilitating the in viti-o cultivation of animal cells. The present invention also relates to media formulations which comprise one or more non-animal derived lipids and/or fatty acids, and more specifically one or more plant lipids and/or fatty acids for cultivation of animal cells in vitro. The formulations of the invention may also comprise one or more of such non-animal or plant peptides and one or more of such non-animal or plant lipids and/or fatty acids. In accordance with the invention, such non-animal or plant-derived peptides and non-animal or plant-derived lipids and/or fatty acids may be used as substitutes for one or more animal-derived culture media components. The invention also provides methods for cultivating animal cells using these non-animal or plant nutrient-based culture media. The media of the present invention arc particularly suited for virus production in animal cells.
Related Art
Cell Culture Media Cell culture media provide the nutrients necessary to maintain and grow cells in a controlled artificial and in vitro environment. The characteristics and compositions of the cell culture media vary depending on iho particular cellular requirements. Important parameters include osmolariry, pH, and nutrient formulations. Media formulations have been used lo cultivate a number of cell types including animal, plant and bacterial cells. Cells cultivated in culture media catabolize available nutrients and produce useful biological substances such as monoclonal antibodies, hormones, growth factors and the like. Such products have therapeutic applications and, with the advent of recombinunt DNA technology, cells can be engineered to produce large quantities of these products. Cultured cells arc also routinely used for the isolation, identification and growth of viruses. Thus, the ability to cultivate cells in vitro is not only important for the study of cell physiology, but is also necessary for the production of useful substances which may not otherwise be obtained by cost-effective means.
Cell culture media formulations are well documented in the literature, and a number of media are commercially available. In early cell culture work, media formulations were based on the chemical composition and physicochcmical properties (e.#., osmolality, pH, etc.) of blood and were referred to as "physiologicul solutions" (Ringer, S., J. Physial. 3:380-393 (1880); Waymouth, C, In: Cells and Tissues in Culture, Vol. 1, Academic Press, London, pp. 99-142 (1965);Waymouth, C, In Vitto 5:109-127 (1970)). However, cells in different tissues of the mammalian body arc exposed to different inicrocnvirυnπtenls with respect to oxygen/carbon dioxide partial pressure and concentrations of nutrients, vitamins, and trace elements. Accordingly, successful in vitro culture of different cell types often require the use of different media formulations. Typical components of cell culture media include amino acids, organic and inorganic salts, vitamins, trace metals, sugars, lipids and nucleic acids, the types and amounts of which may vary depending upon the particular requirements of a given cell or tissue type. Typically, cell culture media formulations are supplemented with a range of additives, including undefined components such as fetal bovine scrum (FBS) (10-20% v/v) or extracts from animal embryos, organs or glands (0.5-10% v/v). While FBS is the most commonly applied supplement in animal cell culture media, other serum sources are also routinely used, including newborn calf, horse and human. These types of chemically undofiπcd supplements serve several useful functions in cell culture media (Lambert, K. J. ei al.. In: Animal Cell Biotechnology, Vol. 1, Spier, R. E. et al., Eds., Academic Press New York, pp. 85-122 (1985)). For example, these supplements provide carriers or chelators for labile or water-insoluble nutrients; bind and neutralize toxic moieties; provide hormones and growth factors, protease inhibitors and essential, often unidentified or undefined low molecular weight nutrients; and protect cells from physical stress and 5- damage. Thus, serum and/or animal extracts are commonly used as relatively low-cost supplements to provide an optimal culture medium for the cultivation of animal cells.
Unfortunately, tho use of serum or animal extracts in tissue culture applications has several drawbacks (Lambert, K. J. et at., In: Animal Cell Biotechnology, Vol. 1, Spier, R. E. ct «... Eds., Academic Press New York, pp. 85-122 (1985)). For example, the chemical composition of these D supplements may vary between lots, even from a single manufacturer. The supplements of animal or human origin may also be contaminated with infectious agents (c.#., mycoplaxma and viruses) which can seriously undermine the health of the cultured cells when these contaminated supplements are used in cell culture media formulations and may additionally pose a health risk in cell therapy and other clinical applications. A major fear is the presence of prions causing spongiform ^ cnccphalopathy in humans or animals. Cell surface chemistry, which is a critical portion of the in vitro microcnvironment for many cell types, can be adversely modified via adsorption or incorporation of scrum or extract proteins. The use of undefined components such as serum or animal extracts also prevents the true definition and elucidation of the nutritional and hormonal requirements of the cultured cells, thus eUminating the ability to study, in a controlled way, the effect >0 of specific growth factors or nutrients on cell growth and differentiation in culture. Moreover, undefined supplements prevent the researcher from studying aberrant growth and differentiation and the disease-related changes in cultured cells. In the industrial production of biological substances, scrum and animal extract supplementation of culture media can also complicate and increase the costs of purification of the desired substances from the culture media due to nonspecific co- 25 purification of scrum or extract proteins.
Serunt'Free Media
To overcome the drawbacks of the use of serum or animal extracts, a number of serum-free media have been developed. These media, which often are specifically formulated to support the culture of a single cell type, incorporate defined quantities of purified growth factors, lipoprotcins and other proteins usually provided by the scrum or extract supplement. Since the components (and concentrations thereof) in such culture media are precisely known, these media are generally referred to as "defined culture media" and often as "serum-free media" or "SFM." Λ number of SFM formulations are commercially available, such as those designed to support the culture of cndothelial cells, keratinocytes, monocytes/macrophagcs, fibroblasts. neurons, lymphocytes, chondrocytes or hepalocytes which arc available from Life Technologies, inc. (Rockvillc, MD).
SFM generally provide several distinct advantages to the user. For example, the use of SFM facilitates the investigation of the effects of a specific growth factor or other medium component on cellular physiology, which may be masked when the cells are cultivated in serum- or cxtract- containing media. In addition, SFM typically contain much lower quantities of protein (SFM are often called "low protein media") than those containing serum or extracts, rendering purification of biological substances produced by cells cultured in SFM far simpler and more cost-effective.
Some extremely simple SFM, which consist essentially of vitamins, amino acids, organic and inorganic sails and buffers have been used for cell culture. Such media (often called "basal media"), however, arc usually seriously deficient in the nutritional content required by most animal cells. Accordingly, most SFM incorporate additional components into the basal media to make the media more nutritionally complex, while maintaining the serum-free and low protein content of the media. Examples of such components include serum albumin from bovine (BSA) or human (HSA), animal- derived lipids such as human Excylc, sterols, etc., and certain growth factors or hormones derived from natural (animal) or recombinant sources.
The use of .such animal-derived supplements in cell culture media, however, also has certain drawbacks. For example, there is a risk that the culture medium and/or products purified from it may be im unogenic, particularly iT the supplements are derived from an animal different from the source of the cells to be cultured. Thus, if biological substances to be used as therapeutics are purified from such culture media, certain amounts of these immunogenic proteins or peptides may be co-purified and may induce an imraunological reaction, including anaphylaxis, in an animal receiving such therapeutics.
To overcome this potential problem, supplements derived from the same species as the cells to be cultured may be used. For example, culture of human cells may be facilitated using HSA as a supplement, while media for the culture of bovine cells would instead use BSA. his approach, however, runs the risks of introducing contaminants and adventitious pathogens into the culture medium (such as HIV or Hepatitis B virus from HSA preparations, or Bovine Spongiform Eπcephalopathy virus from BSA preparations), which cun obviously negatively impact the use of such media in the preparation of animal and human therapeutics. In fact, for safety reasons, the biotechnology industry anil government agencies are increasingly regulating, discouraging and even forbidding the use of cell culture media containing animal-derived products which may contain such pathogens.
Non-animal Peptide Supplements
To overcome the limitations of the use of animal proteins in SFM, several attempts have been made to make animal cell culture media that are completely free of animal proteins. For example, some culture media have incorporated extracts of yeast cells into the basal medium (see, for example, British Patent Application No. GB 901673; Keay, , BiotcchnoL Bioengin. 77:745-764 (1975)) to provide sources of nitrogen and other essential nutrients. In another approach, hydrolysates of wheat gluten have been used, with or without the addition of yeast extract, to promote in vitro growth of animal cells (Japanese Patent Application No. JP 2-49579). Still other media have been developed in which serum is replaced by enzymatic digests of meat, or of proteins such as α-lactalbumin or casein (e.g., peptone), which have been traditionally used in bacterial culture (Lasfargues, E. Y., et al., In Vitro όγ6 W4-500 (1973); Keay, L., BiotecimoL Bioeng. 17:145- 764 (1975); Keay, L., Biυtechnnl. Bioeng. iP:399-411 (1977); Schlager, E.-J., J. Immunol Meth. 7°4:191-199 ( 1996)). None of these approaches, however, provide an optimal culture medium for the cultivation of a variety of animal cells. In fact, the use of wheat peptides is likely to be quite unfavorable for the culture of many animal cells and tissues, since wheat peptides are known to bo toxic or to induce toxic effects in vitro and in vivo, particularly in the cells and tissues of the gastrointestinal systems of some mammals, including humans (Strober, W., et al., Ann. Int. Med. 55:242-256 (1975); Auricchto, S., et al., Pcdiatr. lies. 22(6) 103-H77 (1987)). Moreover, extracts from certain plants, including wheat, barley, rye and oats have been shown to inhibit protein synthesis in cell-free systems derived from animal cells (Colcman, W.H., and Roberts, W.K..
Oiochim. Biophys. Ada 6".9<5:23 -244 (1982)), suggesting that the use of peptides derived from these plants in cell culture media may actually inhibit, rather than stimulate, the growth of animal cells in vitro.
Thus, there is still a need for a scrum-frcc, low-prntein culture medium suitable for cultivation of animal cells, which is completely devoid of animal or human proteins. Such a medium formulation will facilitate the study of the effects of growth factors and other stimuli on cellular physiology, will allow easier and more cost-effective purification of biological substances produced by cultured animal cells in the biotechnology industry, and most importantly, will eliminate the risk of introduction of adventitious animal and human pathogens. The present invention provides such an animal cell culture medium formulation,
BRIEF SUMMARY OF THE INVENTION
The present invention provides culture media formulations comprising non-animal or plant peptides that support the culture of animal cells, preferably as a primary protein source. Specifically, the invention provides a cell culture medium capable of supporting the cultivation of an animal cell in vitro, wherein the medium comprises at least one plant peptide which is not derived from wheat and which is most preferably derived from rice. In another aspect, the media formulations of the invention comprise at least one non-animal or plant lipid and or fatty acid. In yet another aspect, the media formulations of the invention comprise at least one non-animal or plant peptide and at least" one non-animal or plant lipid and/or fatty acid. The invention also provides such media formulations which further comprise an enzymatic digest or extract of yeast cells.
"flic invention also provides a cell culture medium, capable of supporting the cultivation of an animal cell in vitro, comprising an extract of yeast cells, wherein the medium does not further comprise a wheat-derived plant peptide.
The media of the present invention may be IX formulations, or may be concentrated as 10X- 100X, most preferably as 10X, 20X, 25X, 50X or 100X formulations. The basal medium of the present Invention comprises a number of ingredients, including a ino acids, vitamins, organic and inorganic salts, sugars, each ingredient being present in an amount which supports the cultivation of an animal cell in vitro.
The medium of the invention may be used to culture a variety of animal cells, including insect cells (such as from the Spodoptera or Trichuplusa species), avion cells and mammalian cells (including primary cells, established cell lines, CHO cells, COS cells, VERO ceils, BHK cells and human cells). The present invention also provides methods of culturing animal and human cells using the culture medium formulations disclosed herein, comprising die steps of (a) contacting an animal cell with the cell culture medium or the present invention; and (b) cultivating the animal ceil
S under conditions .suitable to support in vitro cultivation.
The present invention also relates to methods for replacing or substituting arumal-dcrived products with non-animal or plant-derived peptides, non-animal or plant lipids/fatty acids (or combinations thereoO, αnd/or enzymatic digests or extracts of yeast cells. Such non-aπiiπal/plaπt- dcrivcd products may be substituted for any number of animal-derived products, including but not limited to blood-derived products (e.g., serum, albumin, antibodies, fibrinogen, factor VHI, etc.), tissue or organ extracts and/or hydrolysates (e.g., bovine pituitary extract (BPE), bovine brain extract, chick embryo extract and bovine embryo extract), and animal-derived lipids and fatty acids, peptones, Excyte, slerols (e.g., cholesterol) and lipoproteins (e.g., high-density and low-density lipoproteins (HDLs and LDI^s, respectively)).
5 The invention further provides compositions comprising the culture media of the present invention and an animal cell, including any of the animal cells described herein.
Other preferred embodiments of the present invention will be apparent to one of ordinary skill in the art in view of the following drawings and description of the invention.
BRIEF DESCRIPTION OF THE FIGURES Figure 1 shows the effect of Plant Powder on the growth of Hybridomu P1F6. Figure 2 shows the effect of Plant Powder on IgC production in Hybridoma P1F6. Figure 3 shows the effect of Plant Powder on specific productivity of Hybridoma P1F6. DETAILED DESCRIPTION OF THE INVENTION
Definitions
t5 In the following description, a number of terms conventionally used in the field of cell culture media are utilized extensively. In order to provide a clear and consistent understanding of the specification and claims and the scope to be given such terms, the following definitions are provided "Culture" or "cell culture" refers to the maintenance of cells in an artificial, in vitro environment. It is to be understood, however, that the term "cell culture" is a generic term and may be used to encompass the cultivation not only of individual cells, but also of tissues, organs, organ systems or whole organisms, for which the terms "tissue culture," "organ culture," "organ system culture" or "organotypic culture" may occasionally be used interchangeably with the term "cell culture."
Tho phrases "cell culture medium," "culture medium" (plural "media" in each case) and "medium formulation" refer to a nutritive solution for cultivating cells and may be used interchangeably.
The term "cultivation" refers to the maintenance of cells in vitro under conditions favoring growth, differentiation or continued viability, in an active or quiescent state, of the colls. In this sense, "cultivation" may be used interchangeably with "cell culture" or any of its synonyms described above. 5 The term "culture vessel" refers to a glass, plastic, or metal container that can provide an aseptic environment for culturing cells.
The term "contacting" refers to the placing ol cells to be cultivated in vitro into a culture vessel with the medium in which the cells are to be cultivated. The term "contacting" encompasses mixing cells with medium, pipetting medium onto cells in a culture vessel, and submerging cells in culture medium.
The term "combining" refers to the mixing or admixing of ingredients in a cell culture medium formulation.
The term "cytokine" refers to a compound that induces a physiological response in a cell, uch as growth, differentiation, senescence, apoplosis, cytotoxicity or antibody secretion. Included 5 in this definition of "cytokine" arc growth factors, interleukiαs, colony-stimulating factors, interferons and lymphokines.
The term "enzymatic digest" refers to a composition comprising a specialized type of extract, namely one prepared by treating the substance to he extracted (e.g., plant components or yeast cells) with at least one enzyme capable of breaking down the components of die substance into simpler -. J forms (e.g., into a preparation comprising mono- or disaccharid s and/or mono-, di- or tripeptides). In this context, and for purposes of the present invention, the term "hydrolysate" may be used interchangeably with the term "enzymatic digest."
The term "extract" refers to a composition comprising a concentrated preparation of the components of a substance, typically formed by treatment of the substance cither mechanically (e.g., by pressure treatment) or chemically (e.g., by distillation, precipitation, enzymatic action or high salt treatment).
The term "lipid" refers generally to water-insoluble organic molecules that can he extracted from cells and tissues by nonpolar solvents. Lipids are generally classified as complex lipids (which contain fatty acids) or simple lipids (which do not contain fatty acids). The complex lipids include acylglycerols, phosphoglyceridcs, sphingolipids and waxes. The simple lipids include terpcncs, steroids and prostaglandins. Tcrpcπes include compounds such as geraniol, limonene, menthol, pinene, camphor and carvone. Steroids include the subgroup "sterols," which are steroid alcohols containing a hydroxyl group and a branched aliphatic chain of eight or more carbon atoms. See generally, Lchningcr, Albert L., Biochemistry, Worth Publishers, Inc. New York, pp. 279-306 (1975), which is herein incorporated by reference.
The term "ingredient" refers to any compound, whether of chemical or biological origin, that can be used in cell culture media to maintain or promote the growth or proliferation of cells. The terms "component" "nutrient" and "ingredient" can be used interchangeably and are all meant to refer to such compounds. Typical ingredients that are αsed in cell culture media include amino acids, salts, metals, sugars, lipids, nucleic acids, hormones, vitamins, fatty acids, proteins and the like. Other ingredients that promote or maintain cultivation of cells ex vivo can be selected by those of skill in the art in accordance with the particular need.
The term "non-animal derived," "non-animal ingredient " or "derived from non-animal sources" refers to the origin of the compound, molecule, peptide, lipid, fatty acid, etc. of interest. Such non-animal sources may include chemical synthesis or synthetic preparations or isolation, preparation or purification of the compound, molecule, peptide, lipid, fatty acid, etc. of interest from bacteria, yeast fungi, and plants.
A cell culture medium is composed of a number of ingredients and these ingredients vary from one culture medium to another. A "IX formulation" refers to any aqueous solution that contains some or all ingredients found in a cell culture medium at working concentrations. The "IX formulation" can refer to, for example, the cell culture medium or to any subgroup of ingredients for that medium. The concentration of an ingredient in a IX solution is about the same as the concen¬ tration of that ingredient found in a cell culture formulation used for maintaining or cultivating cells in vitro. A cell culture medium used for the in vitro cultivation of cells is a IX formulation by definition. When a number of ingredients are present, each ingredient in a IX formulation has a concentration about equal to the concentration of those ingredients in a cell culture medium. For example, RPMl-1640 culture medium contains, among other ingredients, 0.2 g L L-arginine, 0.05 g/L L-asparagine, and 0.02 g L L-aspartic acid. A "IX formulation" of these amino acids contains about the same concentrations of these ingredients in solution. Thus, whch referring to a "IX formulation," it is intended that each ingredient in solution has the same or about the same concentration as that found in the cell culture medium being described. The concentrations of ingredients in a IX formulation of cell culture medium are well known to those of ordinary skill in the art. See Allen R. Liss, Methods For Preparation of Media, Supplements and Substrate For Serum-Free Animal Cell Culture, N.Y. (1984), which is incorporated herein by reference in its entirety. The osmolarity and or pH, however, may differ in a IX formulation compared to the culture medium, particularly when fewer ingredients are contained in the IX formulation.
A "10X formulation" refers to a solution wherein each ingredient in that solution is about 10 times more concentrated than the same ingredient in the cell culture medium. For example, a 10 formulation of RPMT-1 40 culture medium may contain, among other ingredients, 2.0 g L L- argininc, 0.5 g/L L-asparagine, and 0.2 g/L L-aspartic acid (compare IX formulation, above). A "10X formulation" may contain a number of additional ingredients at a concentration about 10 times that found in the IX culture medium. As will be readily apparent, "20X formulation," "25X formulation," "50X formulation" and "100X formulation" designate solutions that contain ingredients at about 20-, 25-. 50- or 100- fold concentrations, respectively, as compared to a IX cell culture medium. Again, the osmolarity and pH of the media formulation and concentrated solution may vary.
Formulation of Culture Media Basal Media
The cell culture media of the present invention are aqueous-based and comprise a number of ingredients in a solution of dcionizcd, distilled water to form a "basal media." Any basal medium can be used in accordance with the present invention. The basal media of the present invention may - include the following ingredients: amiπo acids, vitamins, organic and/or inorganic salts, trace elements, buffering salts and sugars. Preferably, the basal media of the invention comprise one or more amino acids, one or more vitamins, one or more inorganic salts, adcnine sulfate, ATP, one or more trace elements, dcoxyribose, ethanolamiπe, D-glucoεc, glutathione, N-[2-hydroxycthyl]- piperazine-N'-[2-ethancsulfonic acid] (HEPES) or one or more other zwitterion buffers, hypoxanthinc, linoleic acid, lipoic acid, insulin, phenol red, phosphoethanolaminc, putrescine. sodium pyruvalc, thymidiπe, uracil and xanthine. Each of these ingredients may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
Amino acid ingredients which may bo included in the media of the present invention include
L-alanine, L-arginiπε, L-asparagine, L-aspartic acid, L-cystiπe, L-cystcinc, L-glutamic acid, L-gluiamine, glycine, L-histidinc, L-isolcucine, L-Ieuciπe, L-lysinc, L-mcthionine, L-phenylalanine,
L-proline, I^-serinc, L-thrconine, L-lryptophan, L-tyrosine and L-valinc. These amino acids may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
Vitamin ingredients which may be included in the media of the present invention include ascorbic acid magnesium salt, biotin, choliπe chloride, D-Ca^-pantothenate, folic acid, Mnositol, menadione, niacinamidc, nicotinic acid, paraaminobenzoic acid (PABA), pyridoxal, pyridoxinc, rihoflavin, t iaminc-HCl, vitamin A acetate, vitamin B|2 and vitamin L These vitamins may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
Inorganic salt ingredients which may be used in the media of the present invention include CaCl2, KC1, MgCl2, MgSO4, NaCl, NaHCOj, NazHP04, a^PO^-IIzO and ferric citrate cheiate or ferrous sulfate chelatc. These inorganic salts may be obtained commercially, for example from Sigma (Saint Louis, Missouri).
Trace elements which may be used in the media of the present invention include ions of barium, bromium, cobalt iodine, manganese, chromium, copper, nickel, selenium, vanadium, titanium, germanium, molybdenum, silicon, iron, fluorine, silver, rubidium, tin, zirconium, cadmium, zinc and aluminum. These ions may be provided, for example, in trace element salts such
-π- as B (C2H3θ2 2, KBr, CθCI2-6H20, KI, MnClr4H20, Cr(S04). 15H20, CuS04-5H20, NiS04-6H20, H2Se », NaVO3, TiCL,, GeO2, (NH4)6Mθ7θ24- H2 , Na SiO3-9H2θ, FeS 4-7H2O, NaF, AgNO3, RbCl, SnCl2, ZrOCl2-8H20, CdS04-8IΪ20, ZnS04-7H20, Fe(N03)3-9H2O, AlCl.v6HzO.
The specific combinations of the above ingredients, their concentration ranges and preferred concentrations in the basal media are shown in Table I.
Cytυkiπes which may be used in the media of the present invention include growth factors such as epidermal growth factor (EGF), acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), hcpatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-I), insulin- like growth factor 2 (IGF-2), kcratinocyte growth factor (KGF), nerve growth factor (NGF), platelet- derived growth factor (PDGF), transforming growth factor beta (TGF-β), vascular endotheiial cell growth factor (VKGF), transferrin, various iπterleukins (such as IL-1 through IL-18), various colony- stimulating factors (such as granulocyte/macrophage colony-stimulating factor (GM-CSF)), various intcrferons (such as IFN-v) and other cytokines having effects upon hcmatopoletic stem cells such as stem cell factor (SCF) and crythropoictin (Epo). These cytokines may be obtained commercially, for example from Life Technologies, Tnc. (Rockville. Maryland) or R&D Systems (Minneapolis, Minnesota), and may bo citiier natural or rucoinbinant Most preferably, for culture of a wide variety of rruurimalian cells, the basal media will contain EGF at a concentration of about 0.1-100 nanograms/m i 11 i 1 i ter, preferably about 1-10 nanograms/milliliter, and most preferably about 5-10 nanograms per milliliter. Other cytokines, if used, may be added at concentrations that are determined empirically or as guided by the established cytokine art.
Additional ingredients that may be included in the present media are insulin (especially as insulin»Zn++ and transferrin. These additional ingredients, available commercially (for example, from Sigma, St. Louis, Missouri), may be formulated into the present media at the concentration ranges and preferred concentrations shown in Table 1. An iron salt or chclatc (e.g., ferric citrate chclatc or ferrous sulfate) can be used in the present media as a substitute for transferrin. Additionally, rccombinant insulin or zinc based salts (e.g., ZnCl etc.) may be substituted for animal- or human-derived insulin. Table 1. Animal cell culture basal medium component concentrations
Figure imgf000015_0001
Table 1 (continued)
Figure imgf000016_0001
Table 1 (continued)
Figure imgf000017_0001
Table 1 (continued)
Figure imgf000018_0001
Table I (continued)
Figure imgf000019_0001
Complete Media
The above ingredients, when admixed together in solution, form a "basal medium." Other basal media, however, can be cquivalently used in accordance wiϋi the present invention. According to the invention, at least one peptide, extract, enzymatic digest or hydrolysate of a non-animal or a plant and particularly of a plant protein, and/or at least one non-animal -derived or plant-derived lipid and/or fatty acid, is added to the basal medium to formulate the complete culture media of the present invention.
Plants suitable as sources of proteins, peptides, lipids and/or fatty acids in formulating the culture media of the present invention include, but are not limited to, rice, soy, potato, corn and aloe vera. Particularly preferred as a source of plant protein i.s rice. The use of wheat as a source of plant-derived proteins is specifically excluded from the present invention, as extracts and peptide preparations from wheat have been shown to contain inhibitors of protein synthesis in animal cell systems (Coleman, W.H., and Roberts, W.K., Biochim. Biophys. Ada 696:239-244 (1982)) and to induce toxic effects in certain mammalian cells, tissues and organs in vitro and in vivo (Strobcr, W., et al., Ann. Int. Med. 55:242-256 (1975); Aurrichio, S-, et al, Pediatr. Res. 22(6j:703-707 (1987)). However, lipids and or fatty acids from wheat are not excluded from the present invention.
Non-animal or plant peptides for use in formulating the culture media of the present invention may be prepared by digesting non-animal or plant extracts with enzymes such as trypsin or chymotrypsin by methods that are routine in the art. Alternatively, peptides in the form of enzymatic digests or hydrolysates may be obtained commercially, for example from Quest International (Norwich, New York). Non-animal or plant peptides are added to the basal medium at a concentration of about 10-1000 mg/litcr, preferably about 50-500 mg/litcr, and most preferably about 100-200 mg liter.
Tπ another preferred aspect at least one non-animal or plant lipid and/or fatty acid may be added to prepare the media formulations of the present invention. Non-animal or plant lipids fatty acids suitable for use in the present culture media may be obtained from any of the above-described plant sources and others that will be familiar to one of ordinary skill, and from bacteria, yeast and fungi, using methods of lipid/fatty acid isolation (for example, extraction, chromatography, particularly HPLC and the like) that arc well-known in the art Alternatively, plant as well as non-animal lipids/fatty acids and complexes of lipids and/or fatty acids may be obtained commercially, for example from Matreya. Inc. (Pleasant Gap, Pennsylvania) or Sigma (Saint Louis, Missouri). Fatty acids (or combinations thereof) for use in the invention include saturated and unsaturatcd fatty acids. Unsaturatcd fatty acids include monoenic acids, dienoic acids, and higher fatty acids (e.g., tri, tetra, penta and hexaenoic acids, etc.). See generally, Ixhningcr, supra. Particularly preferred lipids/fatty acids for use in the present culture media include, but are not limited to, palmitate, slearate. oleate. linoleate. linolenate, arachidate, myristate, behenate, erucate, Jignocerate, capryiate, caprate, laurate and palmitolcatc (or combinations thereof)- Additionally, plant-derived sterols, known as phytosterols, and fungi- and yeast-derived sterols, known as mycosterols, may be used as the lipid ingredient according to the present invention. Such non-animal derived sterols include, but are not limited to, brassicastcrol, campesterol, desmosterol, ergosterol, fucosterol, lanosterol, stigmastanol (β-sitostcrol), sitosterol, stigmasterol and stigmasterol acetate, all of which arc commercially available, for example from Matreya, Inc. (Pleasant Gap, Pennsylvania) or Sigma (Saint Louis, Missouri). These lipids/fatty acids may be added individually or as mixtures comprising two or more of the above-described lipids/fatty acids, preferably in specific proportions as described in more detail below. Preferably, non-animal or plant lipids/fatty acids are added to a basal medium at concentrations of about 0.00001 to about 10,000 μg/ml, more preferably about 0.0001 to about j 1000 μg/ml, and most preferably ahout 0.001 to about 100 μg/ml.
Together, the basal medium including non-animal or plant-derived peptides and or non- animal or plant-derived lipids/fatty acids formulate complete culture media according to the present invention. These complete media are suitable for use in the culture of a variety of animal cells, as described in more detail below. It may be preferable, however, to further enrich the nutritional lϋ content of the complete media to support faster growth and enhanced production of biologicals by the cultured cells, and to provide a more suitable environment for the culture of fastidious animal cells. To accomplish such enrichment, one or more additional nutrients derived from non-animal sources may be added to the above-described basal or complete media.
In one enriched medium of the invention, the additional nutrients added to the basal medium ϊ or complete medium may comprise extracts of yeast cells (hereinafter "yeast extract" or "YE"), and most preferably ure ultrafiltered YE (hereinafter "yeast extract ultrafiltrate" or "YEU"). Such extracts may be prepared by methods generally known to those skilled in the art of bacteriological or animal cell culture medium formulation, or may be obtained commercially, for example from Sigma (Saint Louis, Missouri), Difco (Norwood, Massachusetts) or Quest International (Norwich, New :0 York). YE or YEU are added to the basal or complete media described above at concentrations of about 10-8000 mg/liter, preferably about 10-100 mg litcr, and most preferably about 50-100 mg/liter. Alternatively, YE or YEU may be added to the basal media at these concentrations, in the absence of whcat-dcrivcd plant peptides, enzymatic digests of animal proteins and peptones, to formulate a suitable animal cell culture medium according to the present invention. 5 The medium ingredients can be dissolved in a liquid carrier or maintained in dry form. If dissolved in a liquid carrier at the preferred concentrations shown in Table I (Lc., a "IX formulation"), the pH of the medium should be adjusted to about 7.0-7.5, preferably about 7.1-7.4, and most preferably about 7.1-7.3. The osmolarity of the medium should also be adjusted to about 275-350 mOsm, preferably about 285-325 mOsm, and most preferably about 300-325 uiOsui. The 0 type of liquid carrier and the method used to dissolve the ingredients into solution vary and can be determined by one of ordinary skill in the art with no more than routine experimentation. Typically, the medium ingredients can be added in any order.
Preferably, the solutions comprising ingredients arc more concentrated than the concentration of the same ingredients in a IX media formulation. The ingredients can be 10- fold more concentrated (10X formulation), 20-fold more concentrated (20X formulation), 25-fold more concentrated (25X formulation), 50-fold more concentrated (50X concentration), or 100-fold more concentrated (100X formulation). More highly concentrated formulations can be made, provided that the ingredient! remain soluble and stable. Sec U.S. Patent No. 5,474,931, which is directed to methods of solubilizing culture media components at high concentrations. Tf the media ingredients arc prepared as separate concentrated solutions, an appropriate
(sufficient) amount of each concentrate is conibiued with a diluent to produce a IX medium formulation. Typically, the diluent used Is water, but other solutions including aqueous buffers, aqueous saline solution, or other aqueous solutions may be used according to the invention.
The culture media of the present invention are typically sterilized to prevent unwanted contamination. Sterilization may be accomplished, for example, by filtration through a low protein- binding membrane filter of about 0.1-1.0 μm pore size (available commercially, for example, from Milliporc, Bedford, Massachusetts) after admixing the concentrated ingredients to produce a sterile culture medium. Alternatively, concentrated subgroups of ingredients may be filter-stcrilizcd and stored as sterile solutions. These sterile concentrates can then be mixed under aseptic conditions with a sterile diluent to produce a concentrated IX sterile medium formulation. Autoclaving or other elevated temperature-based methods of sterilization are not favored, since many of the components of the present culture media arc heat labile and will be irreversibly degraded by temperatures such as those achieved during most heat sterilization methods.
The optimal concentration ranges for the basal medium ingredients are listed in Table 1. These ingredients can be combined to form the basal animal cell culture medium which is then supplemented with cytokines, non-animal or plant peptides and optionally (but preferably) with YE, YEU and or one or more non-animal or plant lipids/fatty acids (or combinations thereof), to formulate the complete media of the present invention. As will be readily apparent to one of ordinary skill in the art, the concentration of a given ingredient can be increased or decreased beyond the range disclosed and the effect of the increased or decreased concentration can be determined using routine experimentation. In a preferred embodiment the concentrations of the ingredients of the medium of the present invention are the concentrations listed in the far right column of Table 1, supplemented with cytokines, non-animal or plant peptides and YE, YEU and/or one or more non- animal or plant lipids/fatty acids as described above. j As will be readily apparent to one of ordinary skill in the art, each of the components of the culture medium may react with one or more other components in the solution. Thus, the present invention encompasses the formulations disclosed in Table 1, supplemented as described above, as well as any reaction mixture which forms after these ingredients arc combinod.
The optimization of the present media formulations was carried out using approaches 0 described by Ham (Ham, R.G., Metlwd for Preparation of Media, Supplements and Substrata for Serum-Free Animal Culture, Alan R. Liss, Inc., New York, pp. 3-21 (1984)) and Waymouth (Waymouth, C, Methods for Preparation of Media, Supplements and Substrata fur Serum-Free Animal Culture, Alan R. Liss, Inc., New York, pp. 23-68 (1984)). The optimal final concentrations for medium ingredients are typically identified either by empirical studies, in single component (5 titration tudies, or by interpretation of historical and current scientific literature. In single component titration studies, using animal cells, the concentration of a single medium component i.s varied while all other constituents and variables arc kept constant and the effect of the single component on viability, growth or continued health of the animal cells is measured.
The present invention also relates to methods for replacing or substituting animal-derived 20 products with non-animal or plant peptides, non-animal or plant lipids and/or fatty acids, and/or enzymatic digests or extracts of yeast cells (or combinations thereof). Such non-animal-, plant- and or yeast-derived nutrients may be substituted for any number of animal-derived culture medium components or sub tituents, including but not limited to blood-derived products, tissue organ/gland extracts, animal-derived fatty acids and lipids, sterols, and lipoproteins. Preferably, blood-derived 25 products and tissue/organ extracts are substituted in the culture media of the invention using one or more of the above-described non-animal or plant-derived peptides, while animal-derived fatty acids/lipids, sterols and lipoproteins arc preferably substituted with one or more of the above- described non-animal or plant-derived lipids fatty acids. Typical blood-derived products that may be replaced in accordance with this aspect of the invention include but are not limited to serum (e.g., 2D fetal bovine serum and calf serum, human scrum, etc.), plasma, albumin (e.g., bovine scrum albumin or human serutn albumin), antibodies, fibrinogen, factor VIU, etc. Typical tissuc/organ gland extracts that may be replaced in accordance with this aspect of the invention include but are not limited to bovine pituitary extract (BPE), bovine brain extract, chicken embryo extract and bovine embryo extract. In accordance with the invention, any animal-derived fatty acid or lipid, including saturated and unsaturated fatly acids lipids that are well-known in the art, may be replaced with one or more of the above-described non-animal or plant-derived lipids/fatty acids. Additionally, animal- derived sterols (e.g., cholesterol) and lipoproteins (e.g., high- and low-density lipoproteins (HDLs and LDLs, respectively)) may be replaced with one or more of the above-described non-ariimal or plant-derived lipids fatty acids in accordance with the invention. Other animal-derived medium components which may be replaced by one or more non-animal or plant-derived nutrients in accordance with the invention can be easily determined by one of ordinary skill in the art by substituting one or more non-animal or plant lipids/fatty acids, non-animal or plant peptides and/or extracts/digests of yeast (or combinations thereof) and testing the effect of such substitution on cell growth by methods that will be familiar to the ordinarily skilled artisan (such as those methods described in the examples below).
The present invention further relates to a kit for replacing one or more ariimal-derived ingredients in a cell culture medium, wherein the kit comprises one or more non-ariimal or plant derived peptides and/or one or more non-animal or plant-derived lipids or fatty acids or combinations thereof.
Use of Culture Media
Cells which can be cultivated in the medium of the present invention are those of animal origin, including but not limited to cells obtained from mammals, birds (avian), insects or fish. Mtujimalian cells particularly suitable for cultivation in the present media include those of human origin, which may be primary cells derived from a tissue sample, diploid cell strains, transformed cells or established cell lines (e.g., HeLa), each of which may optionally be diseased or genetically altered. Other miunmalian cells, uch as hybridomas, CIIO cells, COS cells, VERO cells, IleLa cells, 293 cells, PER-C6 cells, K562 cells, MOLT-4 cells, Ml cells, NS-1 cells. COS-7 ceils, MDBK cells, M CK cells, MRC-5 cells, WT-38 cells, WEIII cells, SP2 0 cells, BHK cells (including BHK- 21 cells) and derivatives thereof, are also suitable for cultivation in the present media. In particular, stem cells and cells used in in vitro virus production may be cultivated in the media of the present invention. Insect cells particularly suitable for cultivation in the present media include those derived from Spodoptera species (e.g., Sf9 or S/21, derived from Spodopteru frugiperdd) or richoplusa species (e.g., HIGH FIVE™ or MG1, derived from Trichoplusa ni). Tissues, organs, organ systems and organisms derived from animals or constructed in vitro or in vivo using methods routine in the art may similarly be cultivated in the culture media of the present invention.
Isolation of Cells
Animal cells for cultiiring by the present invention may be obtained commercially, for example from ATCC (Rockville, Maryland), Cell Systems, Inc. (Kirkland, Washington) or Invitrogcn Corporation (San Diego, California). Alternatively, cells may be isolated directly from samples of animal tissue obtained via biopsy, autopsy, donation or other surgical or medical procedure.
Tissue should be handled using standard sterile technique and a laminar flow safety cabinet. In the use and p ocessing of all human tissue, the recommendations of the U.S. Department of Health and Human Services Centers for Disease Control and Prevention should be followed (Bios fety in Microbiological tmd Binmedical Laboratories, Richmond, J.Y. et al, Eds., U.S. Government Printing Office, Washington, D.C. 3rd Edition (1993)). The tissue should be cut into small pieces1 (e.g., 0.5 x 0.5 cm) using sterile urgical instruments. The small pieces should be washed twice with sterile saline solution upplemented with antibiotics as above, and then may be optionally treated with an enzymatic solution (e.g., collagenase or trypsin solutions, each available commercially, for example, from Lire Technologies, Inc., Rockville, Maryland) to promote dissociation of cells from the tissue matrix.
The mixture of dissociated cells and matrix molecules are washed twice with a suitable physiological saline or tissue culture medium (e.g., Dulbccco' Phosphate Buffered Saline without calcium and magnesium). Between washes, the cells arc ccntrifugcd (e.g., at 200 x g) and then re- suspcnded in serum-free tissue culture medium. Aliquots are counted using an electronic cell counter (such as a Coulter Counter). Alternatively, the cells can be counted manually using a hcmocytometer. Plating; of Cells
The isolated cells can be plated according to the experimental conditions determined by the investigator. The examples below demonstrate at least one functional set of culture conditions useful for cultivation of certain mammalian cells. It is to be understood, however, that the optimal plating Z and culture conditions for a given animal cell type can be determined by one of ordinary skill in the art using only routine experimentation. For routine culture conditions, using the present invention, cells can be plated onto the surface of culture vessels without attachment factors. Alternatively, the vessels can be pre-coatcd with natural, recombinant or synthetic attachment factors or peptide fragments (e.g., collagen or ribronectin, or natural or ynthetic fragments thereof)- Isolated ceils can 0 also be seeded into or onto a natural or syntiietie three-dimensional support matrix such as a preformed collagen gel or a synthetic biopolymeric material, or onto feeder layers of cells. Use of attachment factors or a support matrix with the medium of the present invention will enhance cultivation of many attachment-dependent cells In the absence of serum supplementation.
The cell seeding densities for each experimental condition can be optimized for the specific culture conditions being used. For routine culture in plastic culture vessels, an initial seeding density of O. l-l.O x 10% cells per cmz or about 1.5X the plating concentration routinely used for the ame cells in serum supplemented media i.s preferable.
Mammalian cells arc typically cultivated in a cell incubator al about 37"C, while the optimal temperatures for cultivation of avian, nematodc and insect cells are typically somewhat lower and arc 20 well-known to those of ordinary skill in the an. The incubator atmosphere should be humidified for cultivation of animal cells, and should contain about 3-10% carbon dioxide in air. Culture medium pH should be in the range of about 7.1-7.6, preferably about 7.1-7.4, and most preferably about 7-1- 7.3.
Cells in closed or batch culture should undergo complete medium exchange (i.e., replacing 25 spent media with fresh media) about every 2-3 days, with more or less frequently as required by the specific cell type. Cells in pcrfusion culture (e.g., in bioreactors or feπnentcrs) will receive fresh media on a continuously re-circulating basis. Cell Culture Compositions
The cell culture media of the present invention may also be used to produce cell culture composiiion.s comprising the present media and one or more animal cells. Animal cells preferably used in such compositions include, but arc not limited to, cells obtained from mammals, birds (avian), insects or fish. Mammalian cells particularly suitable for use in such compositions include those of human origin, which may be primary cells derived from a tissue sample, diploid cell trains, transformed cells or established cell lines (e.g., HeLa), each of which may optionally be diseased or genetically altered. Other mammalian cells, such as hybridomas, CHO cells, COS cells, VERO cells, HeLa cells, 293 cells, PER-C6 cells, K562 cells, MOLT-4 cells, Ml cells, NS-1 cells, COS-7 cells, MDBK cells, MDCK cells. MRC-5 cells, WI-38 cells, SP2/0 cells, BHK cells (including BHK-21 cells) and derivatives thereof, are also suitable for use in forming the cell culture compositions of the present invention. Insect cells particularly suitable for use in forming such compositions include those derived from Spυdυptera species (e.g., SJ or SJ2I, derived from Spadυptcra frugiperda) or Trichoplusa species (e.g., HIGH FIVE™ or MG1, derived from Trichoplusa nt). Tissues, organs, organ systems and organisms derived from animals or constructed in vitro or in vivn using methods routine in the art may similarly be used tυ form the cell culture compositions of the present invention. These cell culture compositions may be used in a variety of medical (including diagnostic and therapeutic), industrial, forensic and research applications requiring ready-to-use cultures of " animal cells in scrum-free media. It will be readily apparent to one of ordinary skill in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein are obvious and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which arc included herewith for purposes of illustration only and are not intended to be limiting of the invention.
EXAMPLES
Materials and Methods In each of the following examples, the following materials and methods were generally used: VERO cultures (ATCC) were plated in 25 cm2 ceil culture flasks in duplicate in each medium at about 2.5 x l ^ ceils per flask in 5 ml of medium. No attachment factors or coating of the plastic surface are required for the culture of VERO cells. At 3 to 4 days the cells were removed using standard cell culture techniques. The surface of the culture was first washed with Dulbecco's Phosphate Buffered Saline (DPBS) and then 1.0 ml Trypsin-EDTA (Life Technologies, Inc., Rockville, Maryland) was added. The digest was allowed to sit on the cell surface for 3 to 5 minutes or until the cells rounded up and began to detach from the surface of the flask. The cells were completely detached by vigorous agitation against the palm of the hand and then 1.5 ml of soybean trypsin inhibitor was added to quickly neutralize enzymatic activity. The cells were counted under the microscope using trypan blue straining solution and new cultures plated at 2.5 x 105 cells per 25 cm2 flask. Incubation was at 37°C in 5% CO2 in air. The cultures were passaged for a total of 4 subcultures and the mean cells per subculture determined from the counts of the final 3 subcultures (P2 + P3 + P4 + 3).
Example I: Formulation of Basal Cell Culture Medium
A 20 liter volume of distilled, deionizcd water (hereinafter "ddH2O") was obtained and a sufficient volume (about 200-300 ml) of 5N HC1 was added to decrease the pH of the water to about 0.80. To this water were added the trace elements (from lOOOx stock), L-alaninc (0.22 g), L- arginiπe-HCl (9.75 g), L-asparagine-IICl (1.02 g), L-aspartic acid (0.332 g), L-cysteine-HCI-H2O (0.610 g), L-cystine-HCl (2.87 g), glycine (0.188 g), L-glutamic acid (0.268 g), L-histidine-HCl-H2O (1.707 g), (4284 g), L-leuciπe (4.511 g), L-lysine-HCl (5.640 g), L-methionine (1.266 g), I-r-phenylalanine (2.420 g), L-proline (1.00 g), L-serine (1.261 g), L-threonine (3.260 g), L- tryptophan (0.619 g), L-tyrosine-disodium salt (3.429 g), L-valinc (3.434 g), ihymidinc (0.0070 g), glutathione (0.015 g), pyridoxal-HCl (0.025 g), pyridoxinc HCl (0.00062 g), thiaminc-IICI (0.05 g), MgSO (2.45 g) and ferric citrate chelate (0.015 g). The solution was gently mixed by magnetic stirring for about 15 minutes. The pH of the solution was then adjusted to about 5.50 by adding a sufficient volume (about 20-25 iid) of 5N NaOH. NaH*POrt (7.494 g), NaiHPO4 (1.175 g) and ascorbic acid Mg salt (1.25 g) were added and the solution was again gently mixed for about 15 minutes. The pH was then adjusted to about 6.5 withS aOH.
ATP (0.025 g), uracil (0.0075 g), PABA (0.0012 g), D-Ca^-pantothcnatc (0.05 g), riboflavin (0.005 g), NaCi ( 142.50 g), CaCl2 (3.00 g). MgCl2 (3.125 g) and EGF (0.00025 g) were then added. The solution was again gently mixed for about 15 minules, during which lime a 20 nil volume of absolute ethanol was obtained, to which were added vitamin A acetate (0.0035 g), vitamin D2 (0.0025 g), menadioπe (0.00025 g), lipoic acid (0.0019 g) and linoleic acid (0.00088 g). After allowing the compounds to dissolve in the ethanol, the ethanol solution was added to the 20 liter medium solution from above, and the medium solution was gently mixed for about 5 minutes.
Biotin (0.0019 g), folic acid (0.05 g), hypoxanthinc-Na (0.0415 g), xanthine-Na (0.0075 g) and insulin-Zn++ (0.125 g) were added to a 20 ml volume of ddH2O. After allowing the compounds to dissolve in the water, this water solution was added to the 20 liter medium solution from above, and the medium solution was gently mixed for about 5 minutes. The pH r the solution was then adjusted with 5N HC1 or 5N NaOH to about 7.15±0.50. To this solution were then added adcninc sulfate (0.25 g), D-glucosc (97.56 g), cholinc chloride (0.20 g), Mnositol (0.45 g), nicotinic acid (0.00062 g), niacinamidc (0.05 g), sodium pyruvate (3.75 g), 2- deoxyribose (0.0125 g), KC1 (8.0 g), putrcscinc-2HCl (0.0015 g), phosphocthanolaminc (0.03 g), vitamin B12 (0.0125 g), HEPES (45.0 g), NaHCO, (55.0 g) and phenol red (0.10 g). This solution was gently mixed for about 10-15 minutes, the pH was then adjusted with 5N
HC1 or 5N NaOH to about 7.20*0.10, and ddH20 was added to bring the final volume of the solution up to 25.0 liters. The osmolarity of the solution was determined to be about 310±10 mOsm. This basal medium formulation was then filtered through a low protein-binding filter cartridge and stored at 4°C in conditions of diminished light until use.
Example 2: Plant Peptide Screen
Initial studies were designed to formulate a culture medium completely devoid of animal proteins that supports the culture of animal cells. To this end, enzymatic hydrolysates of a variety of non-animal sources were examined as supplements in the basal medium described in Example 1. Hydrolysates of wheat gluten (IIYPEP 4301 I, designated below as "Wheat Hydrolysate 1", m^ IIYPEP 8382, designated below as "Wheat Hydrolysate 2"), soy (HY-SOY) and rice (HYPEP 5115), as well as an extract of baker's yeast (HY-YEST 444) were obtained from Quest International (Norwich, New York) and were formulated into the basal medium of Example 1 at 200 mg/litcr. VERO cells were cultured in the various medium formulations, and cell counts determined, as described above, and were compared to those obtained in basal medium that was unsupplemented (negative control) or supplemented with 500 mg/litcr human scrum albumin (HSA; positive control). Results shown in Table 2 demonstrate mean cell count per 25 cm7 flask over 3 subcultures and relative growth efficiency (RGE) for each or the medium formulations. RGE was calculated by dividing the mean cell count for a given medium formulation by that for the HSA control.
Table 2. Non-Animal Peptide Screen
Figure imgf000030_0001
These results demonstrate that, of the plant peptides tested as supplements for the culture media, the hydrolysate of rice performed most optimally. While yeast and soy extracts alone supported cell growth to ome extent, the results obtained with rice peptide supplementation were significantly higher than those obtained with either soy or yeast extracts, and were nearly three times higher than that for wheat extracts. Thus, rice hydrolysate is favored as a supplement in animal protein-free formulations of culture media suitable for the cultivation of animal cells.
The poor performance of wheat hydrolysate as a medium supplement for the culture of animal cells is not altogether surprising, in light of the results of previous studies demonstrating that extracts of wheat gluten are toxic or induce toxic effects in certain cell types in vitro and in vivo (Strober, W., et al, Ann. Int. Med. «i*:242-256 (1975); Auricchio, S., el al, Pediatr. Res. 22(6) 7Q3- 707 (1987)) and can inhibit protein synthesis in cell free systems of animal cells (Coleman, W.H., and Roberts, W.K., Biachim. Biophys. Ada 696:239-244 (1982)). Accordingly, the use of wheat peptides or hydrolysates is not appropriate for formulation of animal cell culture media acconling to the present invention.
Example 3: Titration of Rice Hydrolysate
To more closely examine their efficacy as supplements for the present media rice hydrolysates were supplemented into basal media at differing concentrations. These media were then used to examine VERO cell growth as described above. Cell counts were compared to those obtained in basal medium that was unsupplemented (negative control) or to Earle's Modified Eagle's Medium (EMEM) supplemented with 5% fetal bovine serum (FBS; positive control). Results shown in Table 3 demonstrate mean cell count and relative growth efficiency (RGE) for each of the medium formulations; RGE was calculated as described in Example 2. In this experiment, the control contained 5% fetal bovine serum (FBS), which is commonly used to grow VERO cells but which is less efficient in the medium than is HSA.
Table 3. Titration of Rice Hydrolysate
Figure imgf000031_0001
Taken together, the results of this study demonstrate that the use of basal medium supplemented with rice hydrolysate at concentrations as low as 100 mg/liter support the growth of VERO cells at least as well as the use of EMEM supplemented with 5% FBS- These results thus demonstrate that rice hydrolysate at concentrations of 100-300 mg/liter is an optimal supplement for use in formulating the animal cell culture media of the present invention.
Example 4: Titration of Yeast Extract and Screening ofAdditiona I Plant Peptides
To examine additional sources of non-animal peptides and vitamins as supplements for the present media, extracts of yeast, soy and potato were obtained from Quest International (Norwich, New York) and were supplemented into basal media at differing concentrations. Yeast extract (YE) was also examined as a co-supplement with rice hydrolysate. These media were then used to examine VERO cell growth as described above. Cell counts were compared to those obtained with EMEM supplemented with 5% FBS. Results shown in Table 4 demonstrate mean cell count and relative growth efficiency (RGE) for each of the medium formulations. RGE was calculated as described in Example 2.
Table 4. Titration of YE and Screening of Additional Plant Peptides
Figure imgf000033_0001
These results demonstrate that supplementation of the basal medium of Example 1 with 100 mg/liter of YE, or with 200 mg/litcr of cither potato or soy extracts, supports the growth of animal cells approximately as well as the positive control medium .supplemented with FBS. Higher concentrations of YE, however, were less optimal, and the highest concentration (6000 mg/liter) may acmally have inhibited cell growth. Thus, YK, and hydrolysates of soy or potato, may be used as sources of non-animal protein for formulation of the animal cell culture media of the present invention.
Surprisingly, VERO cell growth was even more enhanced when a combination of rice hydrolysate and YE was used. In fact, the combination of 100 mg/liter of rice hydrolysate and 100 mg/liter of YE performed as well as plant peptides used at 200 mg/liler, suggesting that enhanced growth may be observed with the specific combination of rice and YE. These findings indicate that, while media comprising a single plant peptide or YE as a sole protein supplement arc sufficient to support animal cell cultivation, the use of plant peptides and YE in combination in animal cell culture media may be particularly favorable.
Example 5: Use of Yeast Extract Ultrafiltrate
To more closely examine the use of yeast extract as a supplement in the present media preparations of YE or an ultrafiltrate of YE ("YEU") were supplemented into basal media in the presence or absence of 100 mg liler of rice hydrolysate. These media were then used to examine VERO cell growth as described above, Cell counts were compared to those obtained in EMEM supplemented with 5% FBS (positive control). Results shown in Table 5 demonstrate mean cell count and relative growth efficiency (RGE) for each of the medium formulations. RGE was calculated as described in Example 2.
Figure imgf000035_0001
1 "- rice" indicates medium not supplemented with 100 mg/L rice hydrolysate. "+ rice" indicates medium supplemented with 100 mg/L rice hydrolysate.
The results of these studies indicate that YEU used as a supplement promotes growth of animal cells at all concentrations tested in the present media and significantly outperforms YE, suggesting that ultrafUtration of YE to yield YEU provides a more optimal supplement for the support of animal cell cultivatiou. Furthermore, these results demonstrate that the combination of YEU and rice hydrolysate as supplements in the present media is preferable over the use of YEU alone, since VERO cell growth was higher in the YEU/rice combination media for all concentrations of YEU tested. Finally, since the 50 mg/liter concentration of YEU performed approximately as well as higher concentrations in rice-supplemented media, the combination of 100 mg/liter rice hydrolysate and 50 mg/litcr YEU appear to be particularly favorable for economic reasons in the formulation of animal protein-free cell culture media for the cultivation of animal cells. Example 6: Titration ofrEGF
To examine the effect of growth factor concentration on the performance of the culture media, recombinant human EGF was added to the basal media of Example 1 at various concentrations. These media were then used to examine VERO cell growth as described above. Cell counts were compared to those obtained in basal medium that was unsupplemented (negative control) or to EMEM supplemented with 5% FBS (positive control). Results shown in Table 6 demonstrate mean cell count and relative growth efficiency (RGE) for each of the EGF concentrations. RGE was calculated as described in Example 2.
Table 6. Titration of EGF
Figure imgf000036_0001
These initial results, with a wide range of EGF concentrations, suggested that a concentration of 10 mg/liter of EGF in the present media is optimal for supporting the growth of animal cells. To more closely examine this effect, these experiments were repeated with a more narrow range of EGF concentrations. The results of these studies arc shown in Table 7-
Table 7. Titration of EGF
Figure imgf000037_0001
The di.screpancy between Tables 6 and 7 at the 5 mg/L concentration of EGF prompted another titrdtion. The results in this table represent the mean cells per 25 cm2 flask in duplicate over 4 subcultures.
Table 8. Titration of EGF
Figure imgf000037_0002
* as % of 0 mg/L control.
For economic reasons 5 mg/L EGF was chosen for this embodiment.
These results indicate d al EGF at concentrations as low as 5 mg/I, in the present culture media will support the growth of VERO cells. Concentrations lower than 5 mg/L, however, may be insufficient in the present formulations.
Taken in combination, the results shown in Examples 1-6 indicate that an optimal culture medium formulation for supporting the cultivation of animal cells is the basal medium formulation shown in Table 1, supplemented with EGF at 5-10 mg/liter, yeast extract (preferably yeast extract ultrafiltrate) at 50-100 mg/liter, and at least one plant peptide (preferably rice peptides or hydrolysate) at 100-200 mg/liter.
Table 9 shows the use of the medium to grow BHK-21 cells in suspension on a shaker platform. In this experiment, 0.2% PLURON1C F68 was added to both the test medium and the EMEM FBS 5% control to reduce shear damage. Counts were made at 72, 96 and 120 hours. As can be scon in Table 9 the test medium performed as well as or better than the control. By 120 hrs the viability began dropping much more rapidly in the control scrum-supplemented medium as compared to this preferred embodiment of the present invention.
Table 9. Growth of BHK-21 Cells in Suspension in Shaker Flasks
Figure imgf000038_0001
Example 7: Supplementation of Media with Plant Lipids and Fatty Acids
To determine whether the performance of the present culture media could be further enhanced using additional plant-derived nutrients, culture media made as described in Example 1, further containing rice peptides as described in Example 3 and one or more plant-derived lipid or fatty acid formulations, were used to culture VERO cells. Cells were plated in T-25 flasks into culture media that were not supplemented with plant-derived lipids or fatty acids (control) or that were supplemented with 5 μg ml, 0.5 μg/ml or 0.05 μg/ml of one of the following plant lipid or fatty acid mixes obtained from Matreya Inc. (Pleasant Gap, Pennsylvania), having constituents present in the indicated percentages:
RM-1: palmitate (6.0%), stcarate (3.0%), oleate (35.0%), linoleate (50.0%), linolenate (3.0%), arachidate (3.0%)
RM-2: palmitate (7.0%), stcarate (5.0%), oleate (18.0%), linoleate (36.0%), linolenate (34.0%)
RM-3: myrlstate (11.0%), palmitate (4.0%), siearate (3.0%), oleate (45.0%), linoleate (15.0%), linolenate (3.0%), arachidate (3.0%), behenatc (3.0%), erucate (20.0%), lignocer te (3.0%)
RM-5: caprylate (7.0%), caprate (5.0%), laurate (48.0%), myristatc (15.0%), palmitate (7.0%), stcarate (3.0%), oleate (12.0%), linoleate (3.0%)
RM-6: myristate (2.0%), palmitate (30.0%), palmitolcatc (3.0%), stcarate (14.0%), oleate ( 1 .0%), linoleate (7.0%), linolenate (3.0%)
Duplicate experiments were performed, and viable cell counts per flask were determined in cultures at passages 1, 2 and 3 and expressed as a percentage of cell counts in control media not supplemented with plant lipids. Results arc shown in Table 10.
Table 10. Effects of Plant-Derived Lipids oα Cell Growth
Figure imgf000040_0001
Figure imgf000041_0001
These results indicate that supplementation of culture media with plant-derived lipid/ralty acid mixtures enhances the growth of VERO cells when compared to control media not containing these lipid/fatty acid mixes. Use of most of the plant lipid/fatty acid mixtures at concentrations of 0.05 to 5 μg/ml in the culture media induced a substantial increase in VERO cell growth over three passages, with the RM-1 mixture apparcnUy providing the most significant increases at each passage. Together with those from the foregoing Examples, these results indicate that cell culture media comprising a combination of plant-derived nutrients, such as plant peptides and plant lipids or fatty acids, are useful in supporting cultivation and growth of mammalian cells.
Example 8: Effect of Plant Powder on Growth and IgG Production in Hybridoma P1F6
250 mg of Plant Powder (aloe vera plant extract Terry Laboratories, Florida) were added to I x 500 ml bottle of 37^ Hybridoma-SFM (12045-084, lot 1010746, Life Technologies, Maryland). The mixture was stirred for approximately 10 minutes and filtered through a 0.2 μm Millipore Durapore filter. All further dilutions were made from this 500 mg/L stock solution.
The following conditions were set up at 1 x 10δ viable cells/ml in T-75 flasks (15 ml volume):
1) liybridoma-SFM Control
2) 500 mg L Plant Powder
3) 400 mg L Plant Powder
4) 300 mg L Plant Powder
5) 200 mg/L Plant Powder
6) 100 mg/L Plant Powder
The flasks were placed in a 37°C incubator in a humidified atmosphere of 8% Cθ2 in air and subcultured every 2 to 3 days for 3 passages. For the fourth passage, replicate T-75 flasks were set up and samples were taken on days 3, 4 and 5 post planting for determination of total cell density, viable cell density and IgG expression. The samples that were used for IgG determination were oentrifuged and the supcrnatants stored al -20°C until assayed. IgG levels were estimated by ELISA using one sample from each of the replicate samples.
As shown in Figure I, the Plant Powder had a positive effect on viable cell density in a dose- depcndcnt manner. Additionally, IgG expression was also improved by addition of the Plant Powder in a dose-dependent manner as seen in Figure 2. Furthermore, as seen in Figure 3, the specific productivity (μg IgG/106 total cells) was slightly increased in the Plant Powder cultures, with the effect most pronounced on day 5 post planting.
A dosc-dcpcndeπt effect on growth and productivity was observed in cultures supplemented with the Plant Powder. The maximal effect was noted at 500 mg L.
Having now fully described the present invention in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the art that the same can be performed by modifying or changing the invention within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope of the invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope of the appended claims.
All publications, patents and patent applications mentioned in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference.

Claims

WΪIAT IS CLAIMED IS:
1. A cell culture medium comprising at least one non-animal or plant-derived peptide with the proviso that said peptide i.s not derived from wheat, wherein said medium is capable of supporting the cultivation of an animal cell in vitro.
2. A cell culture medium comprising at least one non-animal derived or plant-derived lipid or at least one non-animal or plant-derived fatty acid, wherein said medium is capable of supporting the cultivation of an animal cell in vitro.
3. The cell culture medium of claim I, wherein said medium further comprises at least one non-animal or plant-derived lipid or at least one non-animal or plant-derived fatty acid.
4. The cell culture medium of claim 1, said medium further comprising at least one ingredient .selected from the group of ingredients consisting of at least one amino acid, at least one vitamin, at least one inorganic salt, at least one trace clement, at least one plant lipid or fatty acid, adenine sulfate, ATP, deoxyribosc, ethaπolamine, D-glucose, glutathionc, N-[2-hydroxyethyl]piperazine-N'-l2-ethanesulfonic acid] (HEPBS), hypoxanlhiπe, linoleic acid, lipoic acid, insulin, phenol red, phosphocthanolamine, putrescine, sodium pyruvatc, thymidinc, uracil and xanthine.
5. The ceil culture medium (if claim 2, said medium further comprising at least one ingredient selected from the group of ingredients consisting of at least one amino acid, at least one vitamin, at least one inorganic salt at least one trace element, at least one plant lipid or fatty acid, adenine sulfate, ATP, deoxyribosc, elhanolamine, D'glucosc, glutathione, N-[2-hydroxyethy pipcrazinc-N'-[2-eihaπesulfonic acid] (HBPES), hypoxanthine, linoleic acid, lipoic acid, insulin, phenol red, phosphocthanolamine, putrescine, sodium pyruvate, thymidinc, uracil and xanthine.
6. A cell culture medium obtained by combining at least one non-animal or plant- derived pcptido together with on animal cell culture medium, with the proviso that said plant-derived peptide is not derived from wheai, wherein said medium is capable of supporting the cultivation of an animal cell in vitro.
7. A cell culture medium obtained by combining at least one non-animal or plant- derived lipid or at least one non-animal or plant-derived fatty acid together with an arύ al cell culture medium, wherein said medium is capable of supporting the cultivation of an animal cell in vitro.
8. The cell culture medium of claim 2, wherein said lipid or fatty acid is selected from the group consisting of palmitate, stcarate, oleate, linoleate, linolenate, arachidate, myristatc, bchenate, erucate, lignoccrate, caprylatc, capratc, laurate and palmitoleate, and combinations thereof.
9. The cell culture medium of claim 7, wherein said lipid or fatty acid is selected from the group consisting of palmitate, stearatc, oleate, linoleate, linolenate, arachidate, myristate, behenate, erucate, Iignocerate, caprylatc, caprale, laurate and palmitoleate, and combinations thereof.
10. The cell culture medium of any one of claims 2 and 7, wherein said lipid is a sterol.
11. The cell culture medium of claim 10, wherein said sterol is selected from the group consisting of brassicasterol, campestcrol, desmosterol, crgosterol, fucosterol, lanosterol, stigmasianol, sitostcrol, stigmasterol and stigmasterol acetate.
12. The cell culture medium of claim 1, wherein said animal cell is selected from the group of animal cells consisting of an insect cell, an avian cell, a mammalian cell and a fish cell.
13. The coll culiure medium of claim 2, wherein said animal cell is selected from the group of animal cells consisting of an insect cell, an avian cell, a mammalian cell and a fish cell.
14. A method of cultivating an animal cell comprising the steps of
(a) contacting said animal cell with the cell culture medium of claim 1 and
(b) cultivating said animal cell under conditions suitable to support cultivation of said animal cell.
15. A method of cultivating an animal cell comprising the steps of
(a) contacting said animal cell with the cell culture medium of claim 6; and
(b) cultivating said animal cell under conditions suitable to support cultivation of said animal cell.
16. A method of cultivating an animal cell comprising the steps of
(a) contacting said animal cell with the cell culture medium of claim 2; and
(b) cultivating said animal cell under conditions suitable to support cultivation of said animal cell.
17. A method of cultivating an animal cell comprising the steps of
(a) contacting said animal cell with the cell culture medium of claim 7; and
(b) cultivating said animal cell under conditions suitable to support cultivation of said animal cell.
18. A composition comprising the cell culture medium of claim 1 and one or more animal cells.
1 . A composition comprising the cell culture medium of claim 6 and one or more animal cells.
20. A composition comprising the cell culture medium of claim 2 and one or more animal cells.
21. A composition comprising the cell culture medium of claim 7 and one or more animal cells.
22. A method of producing a cell culture medium in which at least one animal-derived component of said cell culture medium is replaced with non-animal-derived components, comprising combining a basal cell culture medium which comprises no animal-derived components with at least one non-animal or plant-derived peptide, wherein each ingredient Is present in an amount which supports the cultivation of an animal cell in vitro.
23. A method of producing a cell culture medium in which at least. one animal-derived component of said cell culture medium is replaced with non-animal-dcrivcd components, comprising combining a basal cell culture medium which comprises no animal- derived components with at least one non-animal or plant-derived lipid or at least one non-animal or plant-derived fatty acid or a combination thereof, wherein each ingredient is present in an amount which supports the cultivation of an animal cell in vitro.
24. A cell culture medium produced according to the method of claim 22.
25. A cell culture medium produced according to the method of claim 23.
26. A kit for replacing one or more animal-derived ingredients in a cell culture medium, comprising at least one non-animal or plant-derived peptide, lipid, fatty acid, or combinations thereof.
27. The cell culture medium of claim 1, wherein the non-animal or plant-derived peptide is derived from any one of bacteria, fungi, yeast, rice, soy, potato, com and aloe vera.
28. The cell culture medium of claim 2, wherein the non-animal or plant-derived lipid or fatty acid is derived from any one of bacteria, fungi, yeast, rice, soy, potato, co and aloe vera.
PCT/US1999/009574 1998-05-01 1999-05-03 Animal cell culture media comprising non-animal or plant-derived nutrients WO1999057246A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US7080798A 1998-05-01 1998-05-01
US09/070,807 1998-05-01
US30295399A 1999-04-30 1999-04-30
US09/302,953 1999-04-30

Publications (3)

Publication Number Publication Date
WO1999057246A1 true WO1999057246A1 (en) 1999-11-11
WO1999057246A8 WO1999057246A8 (en) 2000-10-12
WO1999057246A9 WO1999057246A9 (en) 2001-06-21

Family

ID=26751514

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009574 WO1999057246A1 (en) 1998-05-01 1999-05-03 Animal cell culture media comprising non-animal or plant-derived nutrients

Country Status (1)

Country Link
WO (1) WO1999057246A1 (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066560A2 (en) * 2000-03-07 2001-09-13 Forbes Medi-Tech Inc. Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
EP1181865A1 (en) * 2000-08-23 2002-02-27 Universite Catholique De Louvain Cryoprotective solutions
WO2004078955A1 (en) * 2003-03-03 2004-09-16 Glaxosmithkline Biologicals S.A. Animal-free cell culture method
FR2879214A1 (en) * 2004-12-14 2006-06-16 Pierre Fabre Medicament Sa PEPTIDE FRACTIONS PROMOTING THE GROWTH AND SYNTHESIS OF PRODUCT (S) OF INTEREST IN CELL CULTURE AND / OR TISSUE
NL1029059C2 (en) * 2005-05-17 2006-11-20 Noord Nl Oliemolen Holding B V Peptide preparation for growing and / or growing microorganisms and / or cells.
EP2064314A2 (en) * 2006-09-13 2009-06-03 Abbott Laboratories Cell culture improvements
US7754484B2 (en) * 2005-11-16 2010-07-13 Cognis Ip Management Gmbh Use of esters of unsaturated, physiologically active fatty acids as nutrient media for cell cultures
US7955833B2 (en) 2002-07-09 2011-06-07 Baxter International Inc. Animal protein free media for cultivation of cells
US8021881B2 (en) 1999-09-28 2011-09-20 Baxter Innovations Gmbh Medium for the protein-free and serum-free cultivation of cells
US8080414B2 (en) 1997-06-20 2011-12-20 Baxter Innovations Gmbh Recombinant cell clones having increased stability and methods of making and using the same
EP2500414A1 (en) * 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US8440408B2 (en) 2004-10-29 2013-05-14 Baxter International Inc. Animal protein-free media for cultivation of cells
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9758568B2 (en) 2006-01-04 2017-09-12 Baxalta GmbH Oligopeptide-free cell culture media
CN110257325A (en) * 2019-05-31 2019-09-20 苏州智享众创孵化管理有限公司 A method of the in vitro culture self-healing cell based on aloe extract
WO2020127941A2 (en) 2018-12-21 2020-06-25 Intervet International B.V. Serum free intracellular pathogen vaccine
WO2021123099A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Reassorted isa virus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607852A (en) * 1992-06-04 1997-03-04 Merch & Co., Inc. Process for attenuated varicella zoster virus vaccine production
US5633162A (en) * 1990-10-17 1997-05-27 Glaxo Wellcome Inc. Method for culturing Chinese hamster ovary cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633162A (en) * 1990-10-17 1997-05-27 Glaxo Wellcome Inc. Method for culturing Chinese hamster ovary cells
US5607852A (en) * 1992-06-04 1997-03-04 Merch & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AURICCHIO S, ET AL.: "PREVENTION BY MANNAN AND OTHER SUGARS OF IN VITRO DAMAGE OF RAT FETAL SMALL INTESTINE INDUCED BY CEREAL PROLAMIN PEPTIDES TOXIC FORHUMAN CELIAC INTESTINE", PEDIATRIC RESEARCH, LIPPINCOTT WILLIAMS & WILKINS, NEW YORK, US, vol. 22, no. 06, 1 January 1987 (1987-01-01), US, pages 703 - 707, XP002919505, ISSN: 0031-3998 *
COLEMAN W H, ROBERTS W K: "INHIBITORS OF ANIMAL CELL-FREE PROTEIN SYNTHESIS FROM GRAINS", BIOCHIMICA ET BIOPHYSICA ACTA., ELSEVIER, NL, vol. 696, 1 January 1982 (1982-01-01), NL, pages 239 - 244, XP002919508, ISSN: 0006-3002 *
FRESHNEY R. I.: "CULTURE OF ANIMAL CELLS. MANUAL OF BASIC TECHNIQUE.", 1 January 1987, NEW YORK, ALAN R. LISS., US, article FRESHNEY R I: "CULTURE OF ANIMAL CELLS A MANUAL OF BASIC TECHNIQUE", pages: 74 - 84 + A, XP002919507, 015492 *
KEAY L: "AUTOCLAVABLE LOW COST SERUM-FREE CELL CULTURE MEDIA. THE GROWTH OF L CELLS AND BHK CELLS ON PEPTONES", BIOTECHNOLOGY AND BIOENGINEERING., WILEY & SONS, HOBOKEN, NJ., US, vol. 17, 1 January 1975 (1975-01-01), US, pages 745 - 764, XP002919506, ISSN: 0006-3592, DOI: 10.1002/bit.260170510 *
MURAKAMI H, MASUI H, SATO G H: "SUSPENSION CULTURE OF HYBRIDOMA CELLS IN SERUM-FREE MEDIUM: SOYBEANPHOSPHOLIPIDS AS THE ESSENTIAL COMPONENTS", COLD SPRING HARBOR MONOGRAPH SERIES., COLD SPRING HARBOR LABORATORY, COLD SPRING HARBOR, NY., US, vol. 09, 1 January 1982 (1982-01-01), US, pages 711 - 715, XP002919509, ISSN: 0270-1847 *

Cited By (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46860E1 (en) 1997-06-20 2018-05-22 Baxalta Incorporated Recombinant cell clones having increased stability and methods of making and using the same
US8329465B2 (en) 1997-06-20 2012-12-11 Baxter Innovations Gmbh Recombinant cell clones having increased stability and methods of making and using the same
US8080414B2 (en) 1997-06-20 2011-12-20 Baxter Innovations Gmbh Recombinant cell clones having increased stability and methods of making and using the same
US8084252B2 (en) 1997-06-20 2011-12-27 Baxter Innovations Gmbh Recombinant cell clones having increased stability and methods of making and using the same
USRE46897E1 (en) 1997-06-20 2018-06-19 Baxalta Incorporated Recombinant cell clones having increased stability and methods of making and using the same
US8084251B2 (en) 1997-06-20 2011-12-27 Baxter Innovations Gmbh Recombinant cell clones having increased stability and methods of making and using the same
USRE46745E1 (en) 1997-06-20 2018-03-06 Baxalta Incorporated Recombinant cell clones having increased stability and methods of making and using the same
US9441203B2 (en) 1999-09-28 2016-09-13 Baxalta Innovations Gmbh Medium for the protein-free and serum-free cultivation of cells
US9982286B2 (en) 1999-09-28 2018-05-29 Baxalta Incorporated Medium for the protein-free and serum-free cultivation of cells
US8722406B2 (en) 1999-09-28 2014-05-13 Baxter Innovations Gmbh Medium for the protein-free and serum-free cultivation of cells
US8021881B2 (en) 1999-09-28 2011-09-20 Baxter Innovations Gmbh Medium for the protein-free and serum-free cultivation of cells
WO2001066560A2 (en) * 2000-03-07 2001-09-13 Forbes Medi-Tech Inc. Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
WO2001066560A3 (en) * 2000-03-07 2002-03-28 Forbes Medi Tech Inc Novel derivatives comprising phytosterols and/or phytostanols and alpha-lipoic and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
EP1181865A1 (en) * 2000-08-23 2002-02-27 Universite Catholique De Louvain Cryoprotective solutions
US9163211B2 (en) 2002-07-09 2015-10-20 Baxter International Inc. Animal protein free media for cultivation of cells
US7955833B2 (en) 2002-07-09 2011-06-07 Baxter International Inc. Animal protein free media for cultivation of cells
US8524497B2 (en) 2002-07-09 2013-09-03 Baxter International Inc. Animal protein free media for cultivation of cells
AU2004217807B2 (en) * 2003-03-03 2009-06-25 Glaxosmithkline Biologicals S.A. Animal-free cell culture method
EP2192175A1 (en) * 2003-03-03 2010-06-02 GlaxoSmithKline Biologicals S.A. Animal-free cell culture method
CN1756837B (en) * 2003-03-03 2010-05-26 葛兰素史密丝克莱恩生物有限公司 Animal-free cell culture method
US8034617B2 (en) 2003-03-03 2011-10-11 Glaxosmithkline Biologicals S.A. Cell culture in culture media free of components of animal origin
EP2186885A1 (en) * 2003-03-03 2010-05-19 GlaxoSmithKline Biologicals S.A. Animal-free cell culture method
WO2004078955A1 (en) * 2003-03-03 2004-09-16 Glaxosmithkline Biologicals S.A. Animal-free cell culture method
US10138461B2 (en) 2004-10-29 2018-11-27 Baxalta GmbH Animal protein-free media for cultivation of cells
US8440408B2 (en) 2004-10-29 2013-05-14 Baxter International Inc. Animal protein-free media for cultivation of cells
US9222075B2 (en) 2004-10-29 2015-12-29 Baxalta Incorporated Animal protein-free media for cultivation of cells
US9714411B2 (en) 2004-10-29 2017-07-25 Baxalta GmbH Animal protein-free media for cultivation of cells
US9809796B2 (en) 2004-10-29 2017-11-07 Baxalta GmbH Animal protein-free media for cultivation of cells
US10655099B2 (en) 2004-10-29 2020-05-19 Baxalta Incorporated Animal protein-free media for cultivation of cells
US8748156B2 (en) 2004-10-29 2014-06-10 Baxter International Inc. Animal protein-free media for cultivation of cells
FR2879214A1 (en) * 2004-12-14 2006-06-16 Pierre Fabre Medicament Sa PEPTIDE FRACTIONS PROMOTING THE GROWTH AND SYNTHESIS OF PRODUCT (S) OF INTEREST IN CELL CULTURE AND / OR TISSUE
WO2006064020A1 (en) * 2004-12-14 2006-06-22 Pierre Fabre Medicament Peptide fractions promoting growth and synthesis of desired product(s) into cell and/or tissue culture
US7993923B2 (en) 2004-12-14 2011-08-09 Pierre Fabre Medicament Peptide fractions promoting growth and synthesis of desired product(S) into cell and/or tissue culture
NL1029059C2 (en) * 2005-05-17 2006-11-20 Noord Nl Oliemolen Holding B V Peptide preparation for growing and / or growing microorganisms and / or cells.
WO2006123926A2 (en) * 2005-05-17 2006-11-23 Stichting Tot Innovatie Van Koolzaadprodukten Peptide composition for growing and/or culturing micro-organisms and/or cells
WO2006123926A3 (en) * 2005-05-17 2007-07-12 Noord Nl Oliemolen Holding B V Peptide composition for growing and/or culturing micro-organisms and/or cells
US7754484B2 (en) * 2005-11-16 2010-07-13 Cognis Ip Management Gmbh Use of esters of unsaturated, physiologically active fatty acids as nutrient media for cell cultures
US9758568B2 (en) 2006-01-04 2017-09-12 Baxalta GmbH Oligopeptide-free cell culture media
EP2064314A4 (en) * 2006-09-13 2009-12-30 Abbott Lab Cell culture improvements
US8663945B2 (en) 2006-09-13 2014-03-04 Abbvie Inc Methods of producing anti-TNF-alpha antibodies in mammalian cell culture
RU2518289C2 (en) * 2006-09-13 2014-06-10 Эббви Инк, Method for preparing fed-batch antibody or its fragment (versions)
US8906646B2 (en) 2006-09-13 2014-12-09 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP2527425A1 (en) * 2006-09-13 2012-11-28 Abbott Laboratories Cell culture improvements
JP2016000030A (en) * 2006-09-13 2016-01-07 アッヴィ・インコーポレイテッド Cell culture improvements
US10119118B2 (en) 2006-09-13 2018-11-06 Abbvie Inc. Modified serum-free cell culture medium
JP2010503397A (en) * 2006-09-13 2010-02-04 アボット・ラボラトリーズ Improved cell culture
EP2064314A2 (en) * 2006-09-13 2009-06-03 Abbott Laboratories Cell culture improvements
AU2007294731B2 (en) * 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
EP2532737A3 (en) * 2006-09-13 2013-03-27 Abbott Laboratories Cell culture improvements
US9090867B2 (en) 2006-09-13 2015-07-28 Abbvie Inc. Fed-batch method of making anti-TNF-alpha antibody
US8093045B2 (en) 2006-09-13 2012-01-10 Abbott Laboratories Fed-batch cell culture methods using non-animal-based hydrolysates
EP2500415A1 (en) * 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2500416A1 (en) * 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
JP2013230151A (en) * 2006-09-13 2013-11-14 Abbott Lab Cell culture improvement
EP2500414A1 (en) * 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2500413A1 (en) * 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
US9284371B2 (en) 2006-09-13 2016-03-15 Abbvie Inc. Methods of producing adalimumab
US9234032B2 (en) 2006-09-13 2016-01-12 Abbvie Inc. Fed-batch methods for producing adalimumab
CN102337243A (en) * 2006-09-13 2012-02-01 雅培制药有限公司 Cell culture improvements
US9090688B2 (en) 2011-04-27 2015-07-28 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9365645B1 (en) 2011-04-27 2016-06-14 Abbvie, Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9505834B2 (en) 2011-04-27 2016-11-29 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9255143B2 (en) 2011-04-27 2016-02-09 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9708400B2 (en) 2012-04-20 2017-07-18 Abbvie, Inc. Methods to modulate lysine variant distribution
US9683033B2 (en) 2012-04-20 2017-06-20 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9346879B2 (en) 2012-04-20 2016-05-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9359434B2 (en) 2012-04-20 2016-06-07 Abbvie, Inc. Cell culture methods to reduce acidic species
US9193787B2 (en) 2012-04-20 2015-11-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9957318B2 (en) 2012-04-20 2018-05-01 Abbvie Inc. Protein purification methods to reduce acidic species
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9290568B2 (en) 2012-09-02 2016-03-22 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9234033B2 (en) 2012-09-02 2016-01-12 Abbvie, Inc. Methods to control protein heterogeneity
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9708399B2 (en) 2013-03-14 2017-07-18 Abbvie, Inc. Protein purification using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9522953B2 (en) 2013-10-18 2016-12-20 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9315574B2 (en) 2013-10-18 2016-04-19 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9266949B2 (en) 2013-10-18 2016-02-23 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9499616B2 (en) 2013-10-18 2016-11-22 Abbvie Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9200070B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9688752B2 (en) 2013-10-18 2017-06-27 Abbvie Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9200069B2 (en) 2013-10-18 2015-12-01 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9550826B2 (en) 2013-11-15 2017-01-24 Abbvie Inc. Glycoengineered binding protein compositions
WO2020127941A2 (en) 2018-12-21 2020-06-25 Intervet International B.V. Serum free intracellular pathogen vaccine
CN110257325A (en) * 2019-05-31 2019-09-20 苏州智享众创孵化管理有限公司 A method of the in vitro culture self-healing cell based on aloe extract
WO2021123099A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Reassorted isa virus

Also Published As

Publication number Publication date
WO1999057246A8 (en) 2000-10-12
WO1999057246A9 (en) 2001-06-21

Similar Documents

Publication Publication Date Title
WO1999057246A1 (en) Animal cell culture media comprising non-animal or plant-derived nutrients
US6103529A (en) Animal cell culture media comprising peptides derived from rice
US20140273205A1 (en) Animal cell culture media comprising non animal or plant derived nutrients
US20040171152A1 (en) Animal cell culture media comprising non-animal or plant-derived nutrients
US6692961B1 (en) Defined systems for epithelial cell culture and use thereof
US20050227355A1 (en) Serum-free cell culture media
US20110183375A1 (en) Metal binding compounds and their use in cell culture medium compositions
EP1210410B1 (en) Metal binding compounds and their use in cell culture medium compositions
US6833271B2 (en) Serum-free cell culture media
DE69737455T2 (en) DEFINED SYSTEMS FOR CULTURING EPITHELIAL CELLS AND APPLYING THE SAME
KR20110138269A (en) Method for improved single cell cloning
US20110143432A1 (en) Use of extract of selenium-enriched yeast (se-ye) in mammalian cell culture media formulations
WO2012008920A1 (en) Materials and methods for enhanced iron uptake in cell culture
DK2218775T3 (en) A method of producing a recombinant polypeptide in vitro CHO cell in a serum-free and protein-free culture medium
Iizuka et al. Fe (III)-IDA induces proliferation and sustains functions of various types of cultured cells as a substitute for transferrin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 45/99 UNDER (30) REPLACE "NOT FURNISHED" BY "09/302953"

AK Designated states

Kind code of ref document: C2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1-41, DESCRIPTION, REPLACED BY NEW PAGES 1-43; PAGES 42-45, CLAIMS, REPLACED BY NEW PAGES 44-48; PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase